

CURRICULUM VITAE

PART I. General Information

Name: Rudolph Emile Tanzi

Office Address: Genetics and Aging Research Unit,
MassGeneral Institute for Neurodegenerative Disease,
Massachusetts General Hospital
114 16th Street, Charlestown, MA 02129

Phone: 617-726-6845

Home Address: 73 K Street, Hull MA 02045

E:mail: Tanzi@helix.mgh.harvard.edu

FAX: 617-724-1949

Place of Birth: Providence R.I., U.S.A.

Education:

1980 B.S. Microbiology, University of Rochester, Rochester, New York

1980 B.A. History, University of Rochester, Rochester, New York

1990 Ph.D. Neurobiology, Harvard University, Cambridge, Massachusetts

Academic Appointments:

1990-1992 Instructor in Neurology, Harvard University

1992-1994 Assistant Professor of Neurology, Harvard University

1993-present Faculty Affiliate, Program in Neuroscience, Harvard University

1994-1999 Associate Professor of Neurology, Harvard University

1999-present Professor of Neurology, Harvard University

2008-present The Joseph P. and Rose F. Kennedy Professor of Neurology and Mental Retardation, Harvard University

Hospital Appointments:

1980-1982	Research Technologist, Genetics Unit, Massachusetts General Hospital
1982-1985	Senior Research Technologist, Massachusetts General Hospital
1990-1994	Assistant Geneticist in Neurology, Massachusetts General Hospital
1994-2000	Associate Geneticist in Neurology, Massachusetts General Hospital
2000-present	Geneticist, Massachusetts General Hospital

Major Administrative Responsibilities (MGH):

1995-present	Director, Genetics and Aging Research Unit, Massachusetts General Hospital
1995-1997	Member, Research Computer Advisory Committee, Massachusetts General Hospital
1995-present	Member, Research Council, Massachusetts General Hospital
1997-present	Partners Program of Excellence in Alzheimer's and Other Neurodegenerative Diseases Steering Committee
1997-present	Partners Program of Excellence in Alzheimer's and Other Neurodegenerative Diseases Pre-clinical Research Committee
1997-present	Partners Clinical Neurogenetics Counseling Unit
1999-present	Massachusetts Alzheimer's Disease Research Center Executive Committee
1999-2003	Partners Robolab Executive Committee
2001-2004	Harvard Center for Neurodegeneration and Repair Core A: Center for Translational Neurology Research
2001-2004	Harvard Center for Neurodegeneration and Repair Core D: Center for New Therapeutics
2001-2004	Harvard Center for Neurodegeneration and Repair Core B: Center for Genomics
2003-present	Massachusetts General Hospital Center for Human Genetics Research Faculty Associate

2003-present	Massachusetts General Hospital Center for Human Genetics Research Steering Committee
2003-present	Massachusetts General Hospital Center for Human Genetics Research Search Committee
2003-present	Neurology Department Financial Oversight Committee
2003-present	MassGeneral Institute for Neurodegenerative Disease Executive Steering Committee
2005-present	MGH Genetics and Ethics Committee
2005-present	Boston Autism Consortium (Genetics Working Group)
2007-present	MassGeneral Institute for Neurodegenerative Disease Research Operations Committee

Major Committee Assignments:

National Institute of Health Review Committees:

1989	Mammalian Genetics Study Section (Ad Hoc Reviewer)
1990	Neurology A Study Section (Ad Hoc Reviewer)
1990	National Institute of Aging Gerontology and Geriatrics Review Committee (Ad Hoc Reviewer)
1991	Alzheimer's Disease Center Core (ADRC) Grants (Ad Hoc Reviewer)
1992	Neurological Sciences Study Section Subcommittee 1 (Ad Hoc Reviewer)
1993	Medical Biochemistry Study Section (Ad Hoc Reviewer)
1994	Neurological Sciences Study Section Subcommittee 1 (Ad Hoc Reviewer)
1994	National Institute of Aging Gerontology and Geriatrics Review Committee (Ad Hoc Reviewer)
1995-1999	National Institute of Aging, R03-SEP, Member
1995-1999	National Institute of Aging-Neuroscience (NIA-N) Review Committee, Member and chairperson for various site visits
1999-present	National Institute of Aging ad hoc chairperson for various site visits

2002-2007	Board of Scientific Counselors, National Institute on Aging
National and International Advisory Committees:	
1996-present	Scientific Board of the Fisher Center for Alzheimer's Research.
1996-present	International Scientific Advisory Committee for the International Symposium on Advances in Alzheimer Therapy
1996-2003	Summer Training Course on Experimental Aging Research Permanent Faculty
1997-present	Cure Autism Now (Autism Genetics Resource Exchange) Steering Committee
1998-2004	Washington University, Saint Louis Alzheimer's Disease Research Center Executive External Advisory Committee
1998-2000	Seventh International Conference on Alzheimer's Disease and Related Disorders (WAC 2000) Program Committee
1998-2000	Scientific Advisory Board, Genoplex, Boulder, Colorado
1998-present	Scientific Founder, Scientific Advisory Board, Prana, Melbourne, Australia
1999-2000	Neuroscience Advisory Board, Astra Pharmaceuticals, Worcester, MA
1998-2003	Scientific Advisory Panel, Lexicon Genetics, The Woodlands, Texas
1998-2002	Scientific Advisory Committee, Huntington's Study Group
1999-2004	Coalition for the Cure Steering Committee, Huntington's Disease Society of America
1999-2002	NIMH Alzheimer's Disease Genetics Initiative Interactive Research Program Grant, Coordinator
1999-2004	NIA Consortium on Alzheimer Genetics, Director
1999-2000	National Research Council: Commission on Behavioral and Social Sciences and Education Committee on Future Directions for Cognitive Research in Aging
1999-2003	Joint Steering Committee for Public Policy, Bethesda, MD

1999-2000	Alzheimer's Disease Scientific Advisory Board, Pfizer
1999-2000	Alzheimer's Disease Scientific Advisory Board, Merck
1999-2000	Alzheimer's Disease Scientific Advisory Board, Roche
2000-2007	Cure Autism Now Scientific Advisory Board
2000-2006	Board of Directors, TorreyPines Therapeutics, Inc (formerly Neurogenetics, Inc), La Jolla, CA
2000-present	Scientific Founder, Scientific Advisory Board, TorreyPines Therapeutics, Inc (formerly Neurogenetics, Inc), La Jolla, CA
2000-2007	Program Committee, Society for Neuroscience
2001-2002	Society for Neuroscience Program Committee Section Chairperson, Neurological and Psychiatric
2000-present	Scientific Advisory Board, Institute for the Study of Aging
2000-present	Scientific Advisory Board, Center for ALS Research at John Hopkins
2001-present	Board of Directors, South Shore Alzheimer's Disease Support Group, MA
2001-present	Scientific Advisory Board, Blanchette Rockefeller Neurosciences Institute
2001-present	Scientific Advisory Board, Alzheimer's Association, Boston, MA
2002-2006	Scientific Advisory Board, SAGE-KE
2002-2005	Keystone Symposia Chronic Diseases Study Group
2003-2004	Advisory Board, TIME Magazine Future of Life
2003-2004	Scientific Advisory Board, Aventis
2003-2004	Scientific Advisory Board, Novartis Functional Genomics Institute
2003-present	International Research Centre for Healthy Ageing and Longevity, Sydney
2005-2006	Society for Neuroscience Program Committee Co-Chairperson
2005-2007	Society for Neuroscience Electronics Initiative Committee
2005-2007	Society for Neuroscience Ethics Committee

2005-2006	Society for Neuroscience Program Committee Chairperson
2005-present	ADNI Genetics Working Group
2005-present	Chairperson, Cure Alzheimer's Fund Research Consortium
2006-2007	Chair, Society for Neuroscience, Theme H
2006-2007	Society for Neuroscience Program Committee, Ex-Officio Chairperson
2007-present	Chairperson, Scientific Advisory Board, Blanchette Rockefeller Neuroscience Institute.
2007	Scientific Advisory Board, Seimens Molecular Imaging
2007	Society for Neuroscience Symposium Mentor
2007	McKinsey Neuroscience Scientific Advisory Board
2007	Member, Dana Alliance for Brain Initiatives
2007	Autism Speaks Scientific Advisory Board
2007	Autism Speaks Autism Genetic Resource Exchange
2008	Witness, U.S. Senate Special Committee on Aging Hearing on Alzheimer's Disease Research (with Newt Gingrich and Sandra Day O'Connor)

National Review Committees:

1996-2002	American Federation for Aging Research-Executive Research Committee
1996-2000	Review Board of the Medical and Scientific Advisory Council, Alzheimer's Association
1997-2004	American Academy of Neurology Potamkin Award Selection Committee
2000-present	American Health Assistance Foundation, Scientific Review Board

Professional Societies:

1983-present	American Association for the Advancement of Science (Fellow)
1990-present	Society for Neuroscience

1992-2003	American Society of Human Genetics
1997-2004	American Society for Cell Biology
1997-2004	American Society of Neurochemistry
Editorial Boards:	
1994-present	Experimental Neurology
1996-present	Alzheimer's Disease Review
1996-2001	Neurogenetics
1996-1999	Current Drugs-ID research alert Alzheimers Disease
1998-present	Experimental Gerontology (Associate Editor)
1998-present	inSight (Science and Academic Press)
1998-present	Journal of Anti-Aging Medicine
1998-present	Current Opinion in Central and Peripheral Nervous System Drugs Section Editor (Neurological Disorders and Neuroprotection)
1998-present	Physiological Genomics
1998-present	Neuron
1999-present	Amyloid
1999-present	Journal of Gerontology-Biological Sciences
2000-present	Aging Research Reviews
2000-present	Neuromolecular Medicine
2001-present	The Scientific World (Aging Domain)
2001-present	Mechanisms in Aging and Development
2001-present	Journal of Molecular Neuroscience
2001-present	Neurosignals
2002-present	Science Magazine: SAGE-KE

2002-present	Current Genomics (Co-Editor)
2002-present	Neurodegenerative Disease
2002-2007	The Scientific World, Associate Editor (Aging)
2002-present	Faculty of 1000
2003-present	Letters in Drug Design & Discovery
2003-present	Medicinal Chemistry Reviews
2003-present	Current Alzheimer's Research
2003-present	Journal of Neuroinflammation
2003-present	Journal of Alzheimer's Disease
2004-present	Rejuvenation Research
2004-present	Neurochemical Research
2005-present	Recent Patent Reviews on CNS Drug Discovery
2005-present	Amyloid
2005-present	Aging Cell
2005-present	Molecular Neurodegeneration
2005-present	Current Medicinal Chemistry
2007-present	The Open Genetics Journal
2007-present	The Open Anesthesiology Journal
2007-present	The Scientific World Journal Aging, Principal Editor
2008-present	Journal of Experimental Neuroscience
Awards and Honors:	
1976	Bausch and Lomb Medal for Excellence in Science
1985	National Research Service Award

1988 Winter Conference on Brain Research Fellowship Award

1991 French Foundation Fellowship Award

1993 Pew Scholar in Biomedical Sciences

1993 The Nathan Shock New Investigator Award, Gerontology Society of America

1995 The Metropolitan Life Foundation Award for Medical Research

1996 The Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disorders

1996 Isolation of Presenilin 2 (Third early-onset familial Alzheimer's disease gene) named one of "Top Ten Medical Advances of 1995" by the Harvard Health Letter

1997 The Krasnow Institute Fairfax Lecture Series Distinguished Speaker

1997 Society for Neuroscience Grass Foundation Lecture.

1997 The Erna Struckmann Lecture, Heidelberg, Germany

1997 Alzheimer's Association T.L.L. Temple Foundation Discovery Award for Alzheimer's Disease Research

1998 The Baylor College of Medicine Huffington Center Tenth Anniversary Celebration Honored Speaker

1998 The Alois Alzheimer Award

1999 The Nobel Forum Lecture, Stockholm, Sweden

1999 University of South Florida Institute on Aging - Distinguished Lecture

1999 Fourth Annual Paul Stark Lecture, (U. Rochester, N.Y.)

2001 Higuchi Honorary Lecture (U. Kansas)

2000 Nathan Shock Award Lecture (N.I.A)

2001 Cranston Hall of Fame Inductee, R.I.

2001 Fellow, American Academy for the Advancement of Science

2002 Dean's Distinguished Lecture, U. Arkansas

2002 NIH MERIT Award

2002 AAAS Topical Lecture

2003 TIME Magazine Future of Life Panelist

2003 Ellison Senior Scholar Award

2003 The Smithsonian Pfizer Distinguished Lecture on the Human Genome

2003 Genetic association of insulin degrading enzyme with Alzheimer's disease named a "top ten health story of 2003" by *Newsweek* magazine

2003 ISI Most Highly Cited (Top 100 in Neuroscience)

2004 Ester and Isadore Kesten Memorial Lecture, U.S.C

2004 Arthur Cherkin Memorial Lecture, UC.L.A.

2004 Society for Neuroscience "Public Lecture"

2005 "Oneness of Humanity Award" Global Award, (2004: Mikhail Gorbachev; 2006: Hillary Clinton)

2005 March 30th named "Dr. Rudolph E. Tanzi Day" in Rochester, N.Y.

2005 2005 Simons Lecturer, Boston MA

2006 02138 Magazine "Harvard 100: Most Influential Alumni" (#78/100 chosen from >320,000 alumni)

2006 Cleveland Clinic 26th Annual Research Day Keynote Lecturer

2007 Ronald and Nancy Reagan Research Institute Award

2008 Time Magazine Top Ten Medical Breakthroughs of 2008 (#5-Identification of four novel Alzheimer's disease genes via a genome-wide association scan of 1300 AD families)

2009 Steve DeArmond Lecture, American Academy of Neuropathology

PART II. Research, Training, and Clinical Contributions:

A. Narrative Report of Research Contributions

As Director of the Genetics and Aging Research Unit in the MassGeneral Institute for Neurodegenerative disease, my research is aimed at identifying and characterizing Alzheimer's disease (AD)- and autism-associated gene mutations and variants with the ultimate goal of defining the molecular, cellular, and biochemical events leading to neuronal cell death in the brains of AD victims. A significant portion of AD involves inheritance of defective genes variants and mutations that influence one's lifetime risk for the disease. To date, four different genes have been firmly implicated to play a role in familial Alzheimer's disease (FAD). Our Unit has been intimately involved with the discovery of three of these genes, including three (the amyloid β protein precursor [*APP*], presenilin 1 [*PSEN1*], and presenilin 2 [*PSEN2*]) that harbor defects causing "early-onset" forms of the disease with 100% certainty under 60 years old. Our studies are targeted toward determining the pathogenic mechanisms by which gene defects or variants contribute to the neurodegenerative process in the brains of patients with AD.

In prevalence studies, we have found that mutations in *APP* appear to cause approximately 3 % of FAD, while those in the presenilin 1 (chromosome 14) and presenilin 2 (chromosome 1) genes are responsible for at least half of all early onset FAD cases. Several late-onset AD genetic risk factors also remain to be identified. In fact, the known AD genes probably account for only 10 - 30% of the genetic variance of AD. Thus, we have been carrying out human genome screens aimed at identifying novel AD genes and have identified several promising chromosomal regions for new AD genes that are currently being pursued. We have identified AD candidate genes on chromosomes 9, 10, and 12 as ubiquilin 1, insulin degrading enzyme, and alpha-2-macroglobulin, respectively. An in-depth understanding of the normal function of the AD genes and how mutations and variants of these genes can lead to β -amyloid deposition, neuronal cell death, and dementia will be invaluable for the development of novel treatments for AD. Along these lines, our overarching goal is to translate knowledge gained regarding genetic mechanisms of neuropathogenesis of AD into drug discovery. To accelerate this process, we have completed a genome-wide association study for novel AD genes using 1300 families and 500K and 1M single nucleotide polymorphism genotyping arrays. We have also completed a genome-wide association screen of families with autism (N=3700) and identified novel candidate genes on chromosomes 5 and 16. Our research in both AD and autism follows a basic roadmap starting with disease gene discovery, then proceeding into translational and functional studies to identify pathogenic gene variants and mutations, followed by molecular biological and biochemical studies to elucidate pathways that have been impacted by disease-associated gene changes, and finally progressing to novel drug screening to identify small molecules or supplements that can halt or reverse pathogenic molecular and biochemical phenotypes at the cellular level. In this manner, the discovery and characterization of novel disease genes engenders improves our means for both predicting and preventing the onset of complex genetic diseases.

B. Funding Information (Current):

Federal:

1998-2013	NIH P01	P.I. (Proj. 2)	Presenilin biology and Alzheimer's Disease.
1999-2013	NIMH R37	P.I.	Search for Novel Alzheimer's Disease Genes (Merit Award).
1999-2014	NIA ADRC	Core Leader	Genetic Analysis of Alzheimer's Disease.

Non-Federal:

2001-present	Tippins Fnd.	P.I.	Genetic Studies of AD
2005-present	Cure Alz. Fund	P.I.	Alzheimer's Genome Project

C. Report of Current Research Activities:

As Director of the Genetics and Aging Research Unit, the focus of my research is in identifying and characterizing the genetic and environmental factors involved in neurodegeneration in Alzheimer's disease and biochemical abnormalities in autism. In addition to identifying risk factors for Alzheimer's disease and autism, the Genetics and Aging Research Unit addresses the mechanisms underlying the etiology and pathogenicity of the genes responsible for Alzheimer's disease through the application of molecular, cell biological, and biochemical strategies. Our ongoing research in AD and autism follows a basic roadmap, which includes disease gene discovery, translational and functional studies to identify pathogenic gene variants and mutations, molecular biological and biochemical studies to elucidate pathways that have been impacted by disease-associated gene changes, and novel drug screening assays to identify small molecules or supplements that can halt or reverse pathogenic molecular and biochemical phenotypes at the cellular level. The Genetics and Aging Research Unit currently consists of eight laboratories including, my own and those of Suzanne Guenette, Ph.D., Doo Kim, Ph.D., Dora Kovacs, Ph.D., Robert Moir, Ph.D., Wilma Wasco, Ph.D., and Zhongcong Xie, M.D., Ph.D. Affiliate laboratories include those of Giuseppina Tesco, M.D., Ph.D., Ashley Bush, M.D., Ph.D., Lee Goldstein, M.D., Ph.D., Jack Rogers, Ph.D., and Xudong Huang, Ph.D.

D. Report of Teaching:

1. Local Contributions

Harvard Medical School Courses

1987-1993,

- Course in Genetics 706.0: Molecular Neurogenetics of Human Disease, (J.F. Gusella, X.O. Breakfield)
- Lecturer
- 10-12 medical and graduate students
- Preparation of one 3-hour lecture

1992 - HST130/Neuro 200 Introduction to Neurobiology (G. Fischbach)
- Lecturer
- 50 medical and graduate students (HMS and MIT)

2000 Didactic Teaching Conference Series in Renal Division, Harvard Institutes of Medicine.

2000-2003 Neurodegenerative Diseases (Course Co-leader)

2001-2002 Undergraduate Thesis Research, Melissa Tukey, Harvard U.

2003-present Doctoral thesis research, Alice Lu, Neuroscience, Harvard Medical School.

2009 Genetics in Medicine

Harvard Continuing Medical Education Courses, Seminars, Grand Rounds (selected):

1994 MGH Neurology Grand Rounds

1994 Gastrointestinal Unit Grand Rounds

1994 MGH Neurology Department "Neurology in the 1990's" half-day session on Dementia

1995 Cancer Center Seminar Series

1996 Anesthesiology Grand Rounds

1998 Neuroscience Seminar Series

1999 MGH Brain and Psyche Symposium

2000 Longwood Medical Grand Rounds

2003	Partners Symposium on Neurodegenerative Disease
2003	Boston Neurology and Psychiatry Society
2004	MGH Medical Grand Rounds
2004	MGH Presidents Council Lecture
2004	Springfield Humanics Lecture
2004	MGH Neurology Residents Seminar Series
2004	MGH Annual Bulfinch Lecture
2004	MGH Public Leaders Day Lecture
2005	Grand Rounds – Department of Anesthesiology
2006	Presenilin Program Project Lecture Series

Names of Advisees and Trainees (selected)

Students:		Current Position
1990-1992	Tricia Huang, Harvard	Physician
1992-1994	Sarada Gurubhagavatula, Harvard	Physician
1998-2000	Genevieve Konopka, Harvard	Post-doctoral Fellow, Wisconsin
1998-2000	Tallessyn Grenfell, M.I.T	Industry
1998-2001	Sanjay Basu, M.I.T.	Physician
2001-2002	Melissa Tukey, Harvard	Physician
2003-2008	Alice Lu	Biotech Consultant
2004-2006	Shinjita Das,	Medical Student, U.T.S.W.
2004-2005	Sam Bride	Resident
2004-present	Stephanie Soccia	Graduate Student, Boston U.,
2005	Katya Tseiltin,	Medical Student, Temple U.

2005-2006	Matthew McKay,	Undergraduate, U. Rochester
2006	David Norton	Undergraduate, Conn. College
2006-2007	Sarah Bourne	Undergraduate, Harvard U.
2008	Lucille Gotta	Undergraduate, Conn. College
2008	Jesse Stevenson	Undergraduate, Conn. College
2009	Gregory McKay	Undergraduate, U. Rochester
2009	Rachel Blaire	Undergraduate, U. Arizona
2009	Jackie Greb	Undergraduate, Colby
2009	Daniel Childs	Undergraduate, Brigham Young U.

Post-doctoral Fellows:

1991-1993	Wilma Wasco, Ph.D.,	Assoc. Prof. of Neurology, Harvard
1991-1994	Sandra Gaston, Ph.D.	Faculty, M.I.T.
1992-1994	Ashley Bush, M.D., Ph.D.	Prof., Melbourne U.
1993-1995	Dora Kovacs, Ph.D.	Assoc. Prof. of Neurology, Harvard
1994-2000	Tae-Wan Kim, Ph.D.	Assoc. Prof. of Neurology, Columbia
1994-1996	Suzanne Guenette, Ph.D.	Assist. Prof. of Neurology, Harvard
1994-1998	Robert Moir, Ph.D.,	Assist. Prof. of Neurology, Harvard
1996-1998	Giuseppina Tesco, M.D.	Assist. Prof. of Neurology, Harvard
1998-2002	Aleister Saunders, Ph.D.	Assoc. Professor, Drexel U.
1999-2002	Lars Bertram, M.D.,	Asst. Prof. of Neurology, Harvard
2000-2002	Joy Goto, Ph.D.	Asst. Prof, City of Hope
2000-present	Zhongcong Xie, M.D.	Asst. Professor, Anesthesia, Harvard
2002-2005	Young Ho Koh, Ph.D.	Government Researcher, S. Korea

2003-present	Minji Kim, Ph.D.	Instructor in Neurology, Harvard
2003-present	Mikko Hiltunen, Ph.D.	Professor, U. Kuopio
2003-present	Airong Li, Ph.D.	Instructor in Neurology, Harvard
2007-present	Can Zhang, M.D., Ph.D.	Post-doctoral Fellow, Harvard
2008-present	Jaehong Suh	Post-doctoral Fellow, Harvard

2. Regional, National or International Contributions

a. Invited Presentations (selected):

1987	FASEB Conference on Somatic Cell Genetics, Vermont
1988	FESN Study Group on "Molecular Genetic Mechanism in Neurological Disorders", Geneva, Switzerland
	Cold Spring Harbor Banbury Center-"The Molecular Biology of Alzheimer's Disease", New York
	World Federation of Neurology Research Group on Dementia International Symposium on Alzheimer's Disease, Finland
	Fifth Pualo Foundation International Symposium-"Pathobiology of Alzheimer's Disease", Finland
	Alzheimer Disease-New Horizon, Tokyo
	International Workshop: "Molecular Biology of Human Genes", Osaka
	World Federation of Neurology-Plenary Symposium Speaker, New Delhi
1989	Fondation IPSEN-"Biological Markers of Alzheimer disease", Toulouse, France
	International Symposium on Dementia, Niigata, Japan
	National Down Syndrome Society-"Molecular Genetic Analysis of Down Syndrome", New York
	EMBO Workshop on Chromosome 21: Impact of the New Genome Technology in Human Genetics, Santa Margherita, Italy
	13th Taniguchi International Symposium on Brain Sciences, La Jolla, CA

- NATO Advanced Workshop on "Regulation of Extravascular Fibrinolysis in Nervous System Development and Disease", Maratea, Italy
- 1990 National Institute of Child Health and Human Development Workshop on "Genotype-Phenotype Correlations in Down Syndrome", Bethesda, MD
- Dahlem Conference on "New Biological Approaches to Neurological Disorders: Pathogenesis and Treatment", Berlin
- Long Island Alzheimer's Foundation International Symposium on Alzheimer's Disease and Related Dementias, New York
- 1991 Cold Spring Harbor Banbury Center Congressional Workshop on "Aging", New York
- VI International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Zurich, Switzerland
- International Society for Neurochemistry 13th Biennial Meeting, Symposium Speaker, Sydney, Australia
- Peptidases and Neuropeptide Processing, Australia
- Long Island Alzheimer's Foundation Second Annual International Symposium on Alzheimer's Disease and Related Dementias, NY
- 1992 French Foundation Workshop-"Brain Amyloid and Blood and Spinal Fluid Tests for Alzheimer Disease", Los Angeles
- Cold Spring Harbor-"Molecular Biology of Aging", New York
- Keystone Symposium on "Advances in Understanding Neurodegenerative Disorders", Montana
- Third International Conference on Alzheimer's Disease and Related Disorders, Padova, Italy
- National Institute of Aging Satellite Symposium/Society for Neuroscience, Anaheim, California, USA
- Gerontology Society of America 45th Annual Meeting Plenary Lecture, Washington, D.C.
- 1993 VII International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Zurich, Switzerland

- Keystone Symposium on "Molecular Biology of Aging", Lake Tahoe, California
- Fondation IPSEN- Lyon/Dijon, France
- The Second International Symposium on Dementia, Oiso, Japan.
- Second Annual IBC Alzheimer's Disease Conference, Philadelphia
- 1994 The XIXth Collegium International Neuropsychopharmacologicum,
Symposium on Alzheimer's Disease (Chairperson), Washington, D.C.
- Neurodegenerative Disorders: Common Molecular Mechanisms, Jamaica
- Human Molecular Genetics, Banbury Center, Cold Spring Harbor
- Recent Developments in Alzheimer Disease, London
- Neuroscience 1994, Finland (Plenary Lecture) Kuopio, Finland
- Third IBC Alzheimer's Disease Conference (Chairperson), Philadelphia
- 1995 Keystone Symposia conference on "The Molecular and Cellular Basis of Human
Neurodegenerative Disease". (Chairperson of Genetics Session)
- Gordon Research Conference on the Biology of Aging
- U. Texas Health Science Center at San Antonio
- Washington University, St. Louis, MO
- Partners Symposium on Aging and Age-Related Diseases, Massachusetts General
Hospital, Boston, MA
- Gerontological Society of America Plenary Symposium (Chairperson), Los
Angeles, CA
- CHI Alzheimer's Disease: The Promise of New Therapeutics (Chairperson),
Boston, MA
- IBC Fourth Alzheimer's Disease Symposium (Chairperson), Waltham, MA
- National Institute of Aging/Alzheimer's Association Apolipoprotein E
Genotyping in Alzheimer's Disease (Chairperson of Consensus Committee on
Research and Technical Issues)
- 1996 Pew Scholars 1996 Meeting Planning Committee

Keystone Symposium on Signaling in Neuronal Development, Differentiation, and Degeneration, Taos (Chairperson, Degeneration Session)

IBC Fifth Alzheimer's Disease Symposium (Scientific Advisory Board) Oak Brook, IL

Fifth International Conference on Alzheimer's Disease, Osaka

N.Y. Academy of Science "Emerging Concepts in Alzheimer's Disease: Therapeutic Directions

Unicare Foundation Keynote Speaker. Lincolnshire, IL

British Congress of Gerontology 1996 (Plenary Speaker), Manchester

University of Kuopio 20th Anniversary of the Department of Neuroscience and Neurology, Kuopio, Finland

Molecular and Cell Biology of Aging and Disease - Prospects for Healthy Aging Symposium, Heidelberg, Germany

College of American Pathologists, San Diego

Presenilins: Form and Function, Washington, DC

6th International Congress for Cell Biology, San Francisco, CA

U.S.-German Biomedical Research Cooperation/Collaboration Meeting (National Institute of Aging), Washington, DC

1997 Keystone Meeting on Alzheimer's Disease and Related Neurodegenerative Disorders, Durango, CO (Workshop Chairperson)

Neurodegenerative Disorders: Common Molecular Mechanisms, (Plenary Speaker), Ocho Rios, Jamaica

Ipsen Foundation Meeting on "The Presenilins and Alzheimer's Disease", (Meeting Organizer), Paris

IBC Sixth Alzheimer's Disease Symposium (Chairperson), San Francisco

CHI Alzheimer's Disease: Advancing Therapeutics towards the Clinic (Chairperson), Washington, DC

17th International Congress of Biochemistry and Molecular Biology and 1997 Annual Meeting of the American Society for Biochemistry and Molecular Biology, San Francisco

Brain Tumors/Alzheimer's disease from Neuropathology to Molecular Biology (Chairperson), Bali, Indonesia

Approaches to Drug Addiction: Molecular Genetics, Rockville, MD

Society for Neuroscience Advocacy Group, New Orleans, LA

Annual Symposium on the Biology of Aging, University of Kentucky College of Medicine, Lexington, KY

Anlage und Umwelt: Bedeutung für die Entwicklung psychischer Störungen, Basel, Switzerland

1998 American Health Assistance Foundation 25th Anniversary Celebration
San Diego, CA

American Society for Neurochemistry, Denver, CO

5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva

Barbara H. Bowman Memorial Symposium on Molecular Genetics, U. Texas, San Antonio

Gordon Conference on the Biology of Aging: Integrative Mechanisms of Aging, Il Ciocco, Barga, Italy

The Second Congress of Molecular Medicine, Berlin

IBC Seventh Alzheimer's Disease Symposium(Chairperson), Boston, MA

NMHCC Therapeutic Targets in Age-Related Diseases (Program Chairperson), San Diego

Neurodegenerative Diseases: A View Toward the 21st Century, (Invited Speaker), Larrede, Spain

6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam

Society for Neuroscience, (Social Issues Roundtable Lecture), Los Angeles

NIA Transgenic Approaches to the Study of Neurological Diseases and the Aging Nervous System, Bethesda

The Ellison Medical Foundation Symposium on "Evolution of Gene Action in Aging and Longevity", San Francisco

1999 Keystone Symposium on Aging, Durango, CO

Keystone on Molecular Mechanisms in Alzheimer' Disease, Taos

The Ninth Adler Symposium on Neurodegenerative Disease, San Diego

6th Asia/Oceania Regional Congress of Gerontology (Plenary Speaker), Seoul, South Korea

University of South Florida Institute on Aging Distinguished Lecture Series, Tampa

Eccles Institute of Human Genetics Lecture Series, U. of Utah

The Nobel Forum Lecture, Stockhom

50th Mossbach Colloquium (Speaker and Chairperson), Mossbach (Baden)

Rockefeller University Seminars in Clinical Research Series, NY

American Psychiatric Association Symposium on Genetic Dissection of the Nervous System, Washington

Vascular Factors in Alzheimer's disease (Plenary Address), Newcastle upon Tyne

University of Washington Aging Seminar Series, Seattle

2000 Tenth Adler Symposium on Neurodegenerative Disease, San Diego

PEW 2000 Reunion, Puerto Vallarta, Mexico

Gordon Conference on the Biology of Aging, Venture, CA (Special Lecture)

Zurich Meeting on Alzheimer's Disease and Other Dementia's, Zurich, Switzerland (Session Chairperson)

ASENT Meeting, Washington, DC

Cure Autism Now Meeting, LA

World Alzheimer Conference 2000 (Plenary Speaker, Session Chairperson)

Plenary on Neurodegenerative Disease, Rhodes, Greece

NIMH Grace Consensus Meeting on Alzheimer Genetics, Bethesda

Boston Alzheimer's Center, Boston

U. Penn. Neuroscience Retreat (Keynote Speaker), Philadelphia

IPSEN Meeting on Apoptosis and CNS Disorders, Paris

Japan Symposium on Alzheimer's Disease, Ciba

2001 Ninth IBC Meeting Special Lecture

Keystone on Alzheimer's Disease and Vascular Dementia, Durango, CO

Keystone on Neurodegenerative Disease, Steamboat Springs, CO

Fresh Air with Terry Gross (NPR), Philadelphia

CSPAN for Books, Chicago

Alder Meeting, Salk Institute, San Diego

Janssen CNS Summit, Scottsdale

Massachusetts Alzheimer Association Keynote Address, Springfield, MA

Gordon Conference on the Biology of Aging, Oxford

Alzheimer's Association, Keynote Presentation, Warwick, RI

ZMBH Forum 2001, Genes, Proteins and Brain Disease, Heidelberg, Germany

Nathan W. Shock Award Lecture, Baltimore

International Society for Neurochemistry, Buenos Aires

Healthcare Foundation of New Jersey Keynote Address

International Symposium on Molecular Mechanisms and Therapeutic Strategies for Neurodegenerative Diseases, Shanghai, China

Neuronal and Vascular Stress: A New Window on Alzheimer's Disease,
Colorado

National Institute of Health, Latest Links: Genes and Alzheimer's, Bethesda, MD

Brain and Aging Conference 2001, San Diego

2002 Second Scientific Meeting on Alzheimer's, Garmisch, Germany

Adler Meeting on Alzheimer's Disease, Salk Institute, San Diego

AAAS Symposium on Aging, Boston

AAAS Symposium on Alzheimer's Disease (Organizer/Chairperson), Boston

Dean's Distinguished Lecture, U. Arkansas

Crest Theatre Lecture Series, Del Ray, FL

Arizona State University, Phoenix, AZ

International Conference on the Immunology of Aging, Washington, D.C.

Eighth International Conference on Alzheimer's Disease, Stockholm

2003 AAAS Topical Lecture, Denver

TIME Magazine Future of Life Summit, Monterey

American Health Assistance Foundation Symposium, San Diego

Boston Neurological Society, Boston

Adler Meeting, San Diego

Gordon Conference on The Biology of Aging, Ventura

Partners Colloquium on Neurodegeneration, Boston, MA

NIH 50th Anniversary of the Double Helix, Bethesda, MD

Alta Partners CEO Conference (Keynote Address), San Diego, CA

Metropolitan Life Foundation Directors Meeting

Fortune Magazine Brainstorm Conference, Aspen, CO

UCSD Neuroscience Seminar

UCLA Neurogenetics Seminar

Novartis Functional Genomics Retreat

Boston Children's Hospital Neuroscience Seminar

MassGeneral Institute for Neurodegenerative Disease Symposium Keynote

2004 Springfield College Humanics Lecture

MGH Medical Grand Rounds

MGH Presidents Council Lecture

MGH Bulfinch Society Lecture

First International Conference on Longevity, Plenary, Sydney, Australia

IBC World Summit, Plenary, San Diego, CA

Martino Center Lecture, MGH

8th International Montreal/Springfield Symposium, Montreal

Dallas Founders Club., Dallas TX

American Psychiatric Association, Invited Symposiast, NYC, NY

UCSD ADRC Education Conference, Keynote, San Diego

PureTech Ventures Innovation Meeting, Boston

1st Esteve International Symposium on Alzheimer's Disease, Opening Lecture,
Barcelona, Spain

2004 Esther and Isadore Kesten Memorial Lecture, USC, Los Angeles

2004 Arthur Cherkin Memorial Lecture, UCLA, Los Angeles

2004 Society for Neuroscience "Public Lecture", San Diego

2005 18th Massachusetts ADRC Symposium,

En Vivo, Watertown MA

U. Rochester, Dept Neurobiology

Davidson College

Eibsee Meeting, Germany

Harvard Memory and Dementia Symposium

1st International Conference on Alzheimer's Disease, Wash., D.C.

MGH Dept. of Anesthesiology Grand Rounds

Alzheimer's Disease Genetics Symposium, UTSW, Dallas

Mayo Clinic Research Institute, Jacksonville, Florida

2005 Simons Lecture, Boston

Neurodegenerative Disease Symposium, Beijing, China

U. Chicago Neuroscience Day Symposium, Chicago

National Academy of Sciences Chinese-American Frontiers in Science, China

Symposium Lecturer, Gerontology Society of America Meeting, Orlando

AD Roundtable Moderator, Gerontology Society of America Meeting, Orlando

2006

Stanford U. Neuroscience Seminar Series, Palo Alto, CA

Salk/Adler Neuroscience Symposium, La Jolla, CA

Keystone Meeting on Alzheimer's Disease, Breckenridge, CO

MPM/Novartis Neuroscience Symposium, Boston, MA

Harvard Institutes of Medicine, Boston, MA

9th International Geneva/Springfield Symposium, Geneva

N. J. Alzheimer's Association Keynote address, Newark, NJ

Lotos Club, N.Y.C, NY

Ellison Medical Foundation Symposium, Woods Hole, MA

Brown University Neuroscience Seminar Series Lecture, Providence, RI

Alzheimer's Disease: 100 Years and Beyond Pioneer Lecture, Tubingen, Germany

Kearney Visiting Professorship, U. Melbourne, Melbourne, Australia

John Cade Lecture, Melbourne Health Research Institute, Melbourne, Australia

Sheikh Hamdan Bin Rashid al Maktoum Award for Medical Sciences Lecture,
Dubai, UAE

Cleveland Clinic Lerner Research Institute's 26th Annual Research Day Keynote
Address, Cleveland, OH

Neurodegenerative Diseases: Biology & Therapeutics Lecture, Cold Spring
Harbor Laboratories, NY

2007 8th International on AD/PD, Plenary, Salzburg

Molecular Mechanisms of Neurodegeneration, Antigua

Osaka Silver Conference on Molecular Biology, Plenary, Osaka

N.Y.C Chapter, Alzheimer's Association, Plenary, New York

NIA Genetics of Alzheimer's Disease, Washington, D.C.

Early Risk Assessment for Alzheimer's disease, Washington, D.C.

Recent Developments in the Treatment of Alzheimer's Disease, San Diego

Barcelona/Boston Alzheimer's Symposium, Plenary, Barcelona

Alzheimer's Disease Symposium, Plenary, McGill U. Montreal

2008 Alzheimer's Disease Research Seminar Series, Boston U. Boston

Keystone Symposium on Alzheimer's Disease, Keystone, CO

International Conference on Alzheimer's Disease, Symposium, Chicago

CSH Meeting on Neurodegenerative Diseases: Biology & Therapeutics, New York

Blanchette Rockefeller Neuroscience Institute Symposium, Plenary, W. Virginia

Rodman Renshaw Biotechnology Conference, New York

2009 Goldman-Sachs Biotechnology Conference, New York

9th International on AD/PD, Symposium Speaker, Prague

b. Professional Roles in Meeting Organization

- 1994 The XIXth Collegium Internationale Neuropsychopharmacologicum, Symposium on Alzheimer's Disease (Chairperson), Washington, D.C.
- IBC Third Annual Alzheimer's Disease Symposium (Chairperson), Philadelphia.
- 1995 Gerontological Society of America Plenary Symposium (Chairperson), Los Angeles.
- CHI Alzheimer's Disease: The Promise of New Therapeutics (Chairperson), Boston, MA
- IBC Fourth Annual Alzheimer's Disease Symposium (Chairperson), Waltham, MA
- National Institute of Aging/Alzheimer's Association Apolipoprotein E Genotyping in Alzheimer's Disease (Chairperson of Consensus Committee on Research and Technical Issues)
- 1996 Pew Scholars 1996 Meeting Planning Committee, Cozumel, Mexico.
- International Scientific Advisory Committee for the International Symposium on Advances in Alzheimer Therapy.
- 1997 Ipsen Foundation Meeting on "The Presenilins and Alzheimer's Disease", (Meeting Organizer), Paris
- IBC Sixth Annual Alzheimer's Disease Symposium (Chairperson), San Francisco
- 1998 CHI Alzheimer's Disease: Advancing Therapeutics Towards the Clinic (Scientific Advisory Committee and Session Chairperson), Washington
- Workshop: Oxidative Stress in Alzheimer's Disease, (Co-Organizer), Heidelberg
- IBC Seventh Annual Alzheimer's Disease Symposium (Chairperson), Boston
- NMHCC Therapeutic Targets in Age-Related Diseases (Overall Program Chairperson), San Diego
- Seventh International Conference on Alzheimer's Disease and Related Disorders Program Committee, 2000, Washington, DC
- 1999 International Scientific Advisory Committee for the International Symposium on Advances in Alzheimer Therapy

IBC Eight Annual Alzheimer's Disease Symposium (Chairperson), Boston

PEW 2000 Planning Committee

Strategic Research Institute 3rd International Neurodegeneration Conference
Chairperson

- 2000 World Alzheimer Conference 2000 Planning Committee
- 2001 Gordon Conference on the Biology of Aging Vice Co-Chair
- 2002 AAAS Symposium on Alzheimer's Disease Chairperson
- 2003 Gordon Conference on The Biology of Aging Co-Chair
- 2005 AD Roundtable Moderator, Gerontology Society of America Meeting, Orlando
- 2005 Co-Chair Program Committee, Society for Neuroscience, Washington, D.C.
- 2006 Organizer, Keystone Meeting on Alzheimer's Disease
- 2006 Program Committee Chair, Society for Neuroscience, Atlanta
- 2007 Program Committee, 8th International Meeting on AD/PD, Salzburg
- 2007 Molecular Mechanisms of Neurodegeneration, Antigua

b. Professional Roles in Teaching

- 1989-1991 Faculty: American Academy of Neurology Course: Genetics in Neurology (L.P. Rowland)
- 250 combined neurologists (CME), medical, and graduate students, post-doctoral fellows, etc.
- Preparation of syllabus and 2-hour lecture
- 1989-1991 Faculty: Cold Spring Harbor Course on Human Genetic Linkage Analysis (D. Page and E. Lander)
- 25 graduate students and post-doctoral fellows
- Five hours of lecture and on-site training
- 1992 U. Michigan, Department of Genetics: "The Genetics of Aging" Course.
- 150 mixed graduate and medical students
- Three hours of lecture
- 1994 The Buck Center for Research in Aging "Summer Training Course in Experimental Aging"

- 100 mixed medical and graduate students, post-doctoral fellows
- One week contact with five hours of lecture and training in molecular approaches to aging research

1996 "Summer Training Course on Experimental Aging Research"
University of Michigan, Ann Arbor

- 30 mixed post-doctoral fellows and junior faculty members.
- One week contact with five hours of lecture and training in experimental approaches to aging research

Faculty: Cold Spring Harbor Course on Neurobiology of Human Neurological Disease: Mechanisms of Neurodegeneration (W. Mobly, S. Gandy, S. Prusiner)

- 20 graduate and medical students and post-doctoral fellows
- Three hours of lecture and on-site training

Current Topics in Pharmacology Seminar Course, Department of Pharmacology, Boston University School of Medicine

- Two hour session with 15 students presenting and discuss three of my laboratory's current papers followed by a one hour seminar

1998 "Summer Training Course on Experimental Aging Research" San Antonio, Texas

- 30 mixed post-doctoral fellows and junior faculty members
- One week contact with five hours of lecture and training in experimental approaches to aging research

1999-2005 Molecular Biology of Aging at the Marine Biological Laboratory, Woods Hole, Massachusetts (August)

- 15 - 20 students
- One week of contact with two hours of lecture and training in the molecular biology of aging

1999 Cold Spring Harbor Course on Molecular Mechanisms of Human Neurological Disorders, Cold Spring Harbor, N.Y. (June 23-29).

- 20 graduate and medical students and post-doctoral fellows
- Three hours of lecture and on-site training on Alzheimer disease genetics and molecular mechanisms

2000 "Summer Training Course on Experimental Aging Research"
Berkeley, CA

- 30 mixed post-doctoral fellows and junior faculty members.
- One week contact with five hours of lecture and training in experimental approaches to aging research

PART III. BIBLIOGRAPHY:

Original Articles:

1. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, Young AB, Shoulson I, Bonilla E, Martin JB. A polymorphic DNA marker genetically linked to Huntington's Disease. *Nature* 1983; 306: 234-238.
2. Gusella JF, Tanzi RE, Anderson MA, Hobbs W, Gibbons K, Raschtchian R, Gilliam TC, Wallace MR, Wexler NS, Conneally PM. DNA markers for nervous system diseases. *Science* 1984; 225: 1320-1326.
3. Watkins PC, Tanzi RE, Gibbons KR, Tricoli JV, Landes G, Eddy R, Shows TB, Gusella JF. Isolation of polymorphic DNA segments from human chromosome 21. *Nucleic Acids Res.* 1985; 13: 6075-6089.
4. Gusella JF, Tanzi RE, Bader PI, Phelan MC, Stevenson R, Hayden MR, Hoffman KJ, Faryniarz AG, Gibbons K. Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. *Nature* 1985; 318: 75-78.
5. Harper PS, Youngman S, Anderson MA, Sarfarazi M, Quarrell O, Tanzi RE, Shaw D, Wallace P, Conneally PM, Gusella JF. Genetic Linkage between Huntington's disease and the DNA polymorphism G8 in South Wales families. *J. Med. Genet.* 1985; 22: 447-450.
6. Folstein SE, Phillips JA, Myers DA, Chase GA, Abbott MH, Franz ML, Waber PG, Kazazian H, Conneally PM, Hobbs W, Tanzi RE, Faryniarz A, Gibbons K, Gusella JF. Huntington's disease: Two families with differing clinical features show linkage to the G8 probe. *Science* 1985; 229: 776-779.
7. Stewart GD, Tanzi RE, Gusella JF. RFLPs at the (D21S19) locus of chromosome 21. *Nucleic Acids Res.* 1985; 13: 7168.
8. Kittur SD, Antonarakis SE, Tanzi RE, Meyers DA, Chakravarti A, Groner Y, Phillips JA, Watkins PC, Kazazian HH. A linkage map of three anonymous human DNA fragments and SOD 1 on chromosome 21. *EMBO J.* 1985; 4: 2257-2260.
9. Breakefield XO, Bressman SB, Kramer PL, Ozelius L, Moskowitz C, Tanzi RE, Brin MF, Hobbs W, Kaufman D, Kidd KK, Fahn S, Gusella JF. Linkage analysis in a family with dominantly-inherited torsion dystonia. *J. Neurogenet.* 1986; 3: 159-175.
10. Youngman S, Sarafazi M, Quarrel OWJ, Conneally PM, Gibbons KT, Harper PS, Shaw DJ, Tanzi RE, Wallace WR, Gusella JF. Studies of a DNA marker (G8) genetically linked to Huntington's disease in British families. *Human Genetics* 1986; 73: 333-339.
11. St. George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers R, Feldman R, Pollen D, Drachman D, Growdon J, Bruni A, Foncin J-F, Frommelt P, Amaducci L, Sorbi S, Piacentini S, Stewart GD, Hobbs WJ, Conneally PM, Gusella JF.

- The genetic defect causing familial Alzheimer's disease maps on Chromosome 21. *Science* 1987; 235: 885-890.
12. Tanzi, RE, Gusella JF, Watkins PC, Bruns GAP, St. George-Hyslop PH, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL. The amyloid beta protein gene: cDNA cloning, mRNA distribution, and genetic linkage near the Alzheimer locus. *Science* 1987; 235: 880-884.
 13. Wexler NS, Young AB, Tanzi RE, Travers H, Staroza-Reuben-Stein S, Penny JB, Snodgrass SR, Shoulson I, Gomez F, Arriro R, Penchaszadeh G, Moreno R, Gibbons K, Faryniarz A, Hobbs W, Anderson M, Bonilla E, Conneally PM, Gusella JF. Homozygotes for Huntington's disease. *Nature* 1987; 326: 194-197.
 14. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Faryniarz AG, Chao MV, Huson S, Korf BR, Parry DM, Pericak-Vance MA, Collins FS, Hobbs WJ, Falcone BG, Iannazzi JA, Roy JC, St. George-Hyslop PH, Tanzi RE, Bothwell MA, Upadhyaya M, Harper PS, Goldstein AE, Hoover DL, Bader JL, Spence MA, Mulvihill JJ, Aylsworth AS, Vance JM, Rossenwasser GO, Gaskell PC, Roses AD, Martuza RL, Breakefield XO, Gusella JF. Genetic linkage of von Recklinghausen Neurofibromatosis to the nerve growth factor receptor gene. *Cell* 1987; 49: 584-594.
 15. Watkins PC, Eddy R, Beck AK, Vellucci V, Leverone B, Tanzi RE, Gusella JF, Shows TB. DNA sequence and regional assignment of the human follicle-stimulating hormone beta-subunit gene to the short arm of human chromosome 11. *DNA* 1987; 6: 205-213.
 16. Gilliam TC, Tanzi RE, Haines JL, Bonner TI, Faryniarz AG, Hobbs WJ, MacDonald ME, Cheng SV, Folstein SE, Conneally PM, Wexler NS, Gusella JF. Localization of the Huntington's disease gene to a small segment of chromosome 4 flanked by D4S10 and the telomere. *Cell* 1987; 50: 565-571.
 17. Tanzi RE, St. George-Hyslop PH, Haines JL, Polinsky RJ, Nee L, Foncin J-F, Neve RL, McClatchey AI, Conneally PM, Gusella JF. The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid beta protein gene. *Nature* 1987; 329: 156-157.
 18. Tanzi RE, Bird ED, Latt SA, Neve RL. The amyloid beta protein gene is not duplicated in brains of patients with Alzheimer's disease. *Science* 1987; 238: 666-669.
 19. St. George-Hyslop PH, Tanzi RE, Polinsky RJ, Neve RL, Pollen D, Drachman D, Growden J, Cupples LA, Nee L, Myers RH, O'Sullivan D, Watkins PC, Amos JA, Deutsch CK, Bodfish JW, Kinsbourne M, Foncin J-F, Gusella JF. Absence of duplication of chromosome 21 genes in familial and sporadic Alzheimer's disease. *Science* 1987; 238: 664-666.
 20. Cheng SV, Lugo TG, Tanzi RE, Whitney JB III, Fournier RE, Gusella JF. Chromosomal localization of the mouse homologue of the Huntington's disease linked G8 D4S10 marker. *DNA* 1987; Vol. 6:5: 401-407.
 21. Tanzi RE, McClatchey AI, Lamperti ED, V-Komaroff L, Gusella JF, Neve R. Protease

- inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. *Nature* 1988; 331: 528-530.
22. Stewart GD, Hassold TJ, Berg A, Watkins P, Tanzi R, Kurnit DM. Trisomy 21 (Down syndrome): Studying nondisjunction and meiotic recombination by using cytogenetic and molecular polymorphisms that span chromosome 21. *Am. J. Hum. Genet.* 1988; 42: 227-236.
 23. Tanzi RE, Haines JL, Watkins PC, Stewart GD, Hallewell R, Wong, C. Wexler NS, Conneally PM, Gusella JF. Genetic linkage map of human chromosome 21. *Genomics* 1988; 3: 129-136.
 24. Palmert MR, Golde TE, Kovacs D, Tanzi RE, Gusella JF, Usiak MF, Younkin LH, Younkin SG. Alzheimer's disease nucleus basalis and locus coeruleus neurons show increased amyloid protein precursor mRNA lacking the protease inhibitor domain. *Science* 1988; 241: 1080-1084.
 25. Cheng SV, Nadeau J, Tanzi R, Watkins P, Sacchi N, Neve R, Gusella J. Synteny in man and mouse of DNA markers from the chromosomal region linked to familial Alzheimer's disease and Down syndrome. *Proc. Natl. Acad. Sci. (USA)* 1988; 85: 6032-6036.
 26. Patterson D, Gardiner K, Kao F-T, Tanzi R, Watkins P, Gusella J. The mapping of the gene encoding the beta amyloid precursor protein and its relationship to the Down syndrome region of chromosome 21. *Proc. Natl. Acad. Sci. (USA)* 1988; 85: 8266-8270.
 27. Sacchi N, Cheng SV, Tanzi RE, Gusella JF, Drabkin HA, Patterson D, Haines J, Papas TS. The ETS genes on chromosome 21 are distal to the breakpoint of the acute myelogenous leukemia translocation (8;21). *Genomics* 1988; 3: 110-116.
 28. Graw S, Davidson J, Gusella J, Watkins P, Tanzi RE, Neve R, Patterson D. Irradiation reduced human chromosome 21 hybrids. *Somatic Cell Mol. Genet.* 1988; 14: 233-242.
 29. Phelan MC, Morton CC, Stevenson RE, Tanzi RE, Stewart GD, Watkins PC, Gusella JF, Amos JA. Molecular and cytogenetic characterization of a de novo t(5p;21q). *Am. J. Hum. Genet.* 1988; 43: 511-519.
 30. Van Keuren ML, Stewart GD, Bradley CM, Kurnit DM, Neve RL, Watkins PC, Tanzi RE, Gusella JF, Patterson DP. Characterization of an unusual and complex chromosome 21 rearrangement using somatic cell genetics and cloned DNA probes. *Am. J. Hum. Genet.* 1989; 33: 369-375.
 31. Conneally PM, Haines JL, Tanzi RE, Wexler NS, Penchaszadeh GK, Harper PS, Folstein SE, Cassiman JJ, Myers RH, Young AB, Hayden MR, Falek A, Tolosa ES, Crespi S, DiMaio L, Holmgren G, Anvret M, Kanazawa I, Gusella JF. Huntington's disease: No evidence for locus heterogeneity. *Genomics* 1989; 5: 304-388.
 32. Palmert MR, Podlisney MB, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF, Whitehouse PJ, Witker DS, Oltersdorf T, Younkin SG. Analysis of the beta-amyloid

- protein precursor of Alzheimer's disease: mRNAs and protein products. *Adv. Neurol.* 1990; 51: 181-184.
33. St. George-Hyslop and the FAD collaborative Study Group. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. *Nature* 1990; 347: 194-197.
 34. Lerner TJ, Arn E., Anderson MA, Klinger KW, Callen DF, Tanzi RE. Two RFLPs detected by a cosmid at locus D16S144. *Nucleic Acids Res.* 1990; 18: 1085.
 35. Epstein CJ, Korenberg JR, Anneren G, Antonorakis SE, Ayme S, Courchesne E, Epstein LB, Fowler A, Gromer Y, Kemper TL, Lott IT, Lubin BH, Magenis E, Opitz M, Patterson D, Priest JH, Pueschel SM, Rapoport SI, Sinet P-M, Tanzi RE, de la Cruz F. Protocols to establish genotype-phenotype correlations in Down syndrome. *Am. J. Hum. Genet.* 1991; 49: 207-235.
 36. Siddique T, Figlewicz M, Perikak-Vance M, Haines J, Roos RP, Rouleau G, Williams D, Watkins PC, Jeffers A, Sapp P, Hung W, Bebout J., Noore F.R., Nicholson G., Reed R., McKenna-Yasek D., Deng G, Beard C, Brooks BR, Festoff B, Antel J, Tandan R, Munsat TL, Mulder DW, Laing NG, Halperin J, Norris FH, Van den Bergh R, Swerts L, Tanzi R, Jubelt B, Matthews KM, Bosch EP, Horvitz R, Gusella JF, Brown RH, Roses AD. Assignment of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence for genetic heterogeneity. *New Eng. J. Med.* 1991; 324: 1381-1384.
 37. Tanzi RE, Hyman BT. Alzheimer's mutation and translational regulation. *Nature* 1991; 350: 564.
 38. Abe K., Tanzi R.E., Kogure K. Selective induction of Kunitz-type protease inhibitor domain-containing APP mRNA after persistent focal ischemia in rat cerebral cortex. *Neurosci. Lett.* 1991; 125:172-174.
 39. Abe K, Tanzi RE, Kogure K. Induction of HSP70 mRNA after transient ischemia in gerbil brain. *Neurosci. Lett.* 1991; 125: 166-168.
 40. Abe K, St. George-Hyslop PH, Tanzi RE, Kogure K. Induction of β -amyloid precursor protein mRNA after heat-shock in cultured human lymphoblast cells. *Neurosci. Lett.* 1991; 125: 169-171.
 41. Tanzi RE, St. George-Hyslop PH, Gusella JF. Molecular genetics of Alzheimer disease amyloid. *J. Biol. Chem.* 1991; 266: 20579-20583.
 42. Tanzi RE, Watkins PC, Stewart GD, Wexler NS, Gusella JF, Haines JL. A genetic linkage map of human chromosome 21q: Patterns of recombination according to age and sex. *Am. J. Hum. Genet.*, 1992; 50: 551-558.
 43. Hyman BT, Tanzi RE, Marzloff K, Barbour R, Schenck D. Kunitz Protease inhibitor-containing APP immunoreactivity is present in neurons, neuritic plaques and the cerebral vasculature in Alzheimer's disease. *J. Neuropath. Exp. Neurol.* 1992; 51: 76-83.

44. Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL, Tupler, RG, Wasco W, Hyman BT, Haines JL, Jenkins BJ, Kalaitzidaki M, Warren AC, McInnis MG, Antonarakis SE, Karlinsky H, Percy, ME, Connor L, Growdon J, Crapper-McLachlan DR, Gusella JF, St. George-Hyslop PH. Assessment of β amyloid protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. *Am. J. Hum. Genet.*, 1992; 51: 273-282.
45. Wasco W., Bupp K., Magendantz M., Gusella J., Tanzi R.E., Solomon F. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer-associated amyloid β protein precursor. *Proc. Natl. Acad. Sci. (USA)*, 1992; 89: 10758-10762.
46. Tanzi RE, Romano DR, Berger R, Buraczynska MJ, Gaston SM, Kurnit DM, Patterson D, Gusella J, Stewart GD. Sequence tagged sites for a set of mapped markers on chromosome 21. *Genomics*, 1992; 14: 498-502.
47. Karlinsky H, Vaula G, St George-Hyslop P, Haines J, Ridgley J, Bergeron C, Mortilla M, Tupler R, Percy M, Robitaille Y, Noldy N, Yip T, Tanzi R, Gusella J, Becker R, Berg J, Crapper McLachlan D. Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer's disease and a missense mutation in codon 717 of the β -amyloid precursor protein gene. *Neurology*, 1992; 42: 1446-1459.
48. Fidani L, Rooke K, Chartier-Harlin M-C, Hughes D, Tanzi R, Mullan M, Roques P, Rossor M, Hardy J, Goate A. Screening for mutations in the open reading frame and promotor of the beta amyloid precursor protein gene in familial Alzheimer's disease: Identification of a further family with APP717 Val -> Ile. *Hum. Mol. Genet.*, 1992; 1: 165-168.
49. Vaula G, Mortilla M, Tupler R, Lukiw W, Tanzi R, St George-Hyslop P. A novel but non-pathogenic mutation in exon 4 of the amyloid precursor protein (APP) gene. *Neurosci. Lett.*, 1992; 144: 1-2.
50. St George-Hyslop PH, Haines J, Rogaev E, Mortilla M, Vaula G, Pericak-Vance M, Foncin J-F, Montesi M, Bruni A, Sorbi S, Rainero I, Pinessi L, Pollen D, Polinsky R, Nee L, Kennedy J, Macciardi F, Rogaeva E, Liang Y, Alexandrova N, Lukiw W, Schlumpf K, Tanzi R, Tsuda T, Farrer L, Cantu J-M, Duara R, Amaducci L, Bergamini L, Gusella J, Roses A, Crapper-McLachlan D. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. *Nature Genetics*, 1992; 2: 330-334.
51. Haines JL, Trofatter JA, Tanzi RE, Watkins P, Wexler NS, Conneally PM, Gusella JF. Chromosome 21 genetic linkage data set based on the Venezuelan reference pedigree. *Cytogenet. Cell Genet.*, 1992; 59: 88-89.
52. Wasco W, Brook JD, Tanzi RE. The amyloid precursor-like protein gene maps to the long arm of chromosome 19. *Genomics*, 1993; 15: 238-239.
53. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hontati A, Donaldson D, Goto J, O'Regan JP, Deng H-X, Rahman Z, Krizus A, McKenna-Yasek D, Tanzi RE, Halperin

- JJ, Herzfeldt B, Van den Berg R, Hung W-Y, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance M, Haines J, Rouleau GA, Horvitz HR, Brown RH. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature*, 1993; 362: 59-62.
54. Tanzi RE, Wenniger JJ, Hyman BT. Regional distribution and cellular specificity of APP alternative transcripts are unaltered in Alzheimer's disease and control hippocampal formation. *Mol. Brain Res.*, 1993; 18: 246-252.
 55. Hyman BT, Wenniger JJ, Tanzi RE. Nonisotopic in situ hybridization of amyloid precursor protein in Alzheimer's disease: Expression in neurofibrillary tangle bearing neurons and in the micro-environment surrounding senile plaques. *Mol. Brain Res.*, 1993; 18: 253-258.
 56. Wasco W, Gurubhagavatula S, Paradis MD, Romano DM, Sisodia S, Hyman BT, Neve RL, Tanzi RE. Isolation and characterization of the human APLP2 gene encoding a homologue of the Alzheimer's associated amyloid protein precursor. *Nature Genetics*, 1993; 5: 95-100.
 57. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Brzustowicz LM, Devoto M, Peppercorn J, Bush AI, Sternlieb I, Pirastu M, Gusella JF, Evgrafov O, Penchaszadeh GK, Honig B, Edelman IS, Soares MB, Scheinberg IH and Gilliam TC. Identification of the Wilson's disease gene: A copper transporting ATPase with homology to the Menke's disease gene. *Nature Genetics*, 1993; 5: 344-350.
 58. Petrukhin K, Fischer SG, Pirastu M, Tanzi RE, Chernov I, Devoto M, Brzustowicz LM, Cayanis E, Vitale E, Russo J, Matseoane D, Boukgalter B, Wasco W, Gigus AL, Loudiansos J, Cao A, Sternlieb I, Evgrafov O, Parano E, Pavone L, Warburton D, Ott J, Penchaszadeh G, Scheinberg IH, Gilliam TC. Physical mapping and genetic characterization of the Wilson's disease locus. *Nature Genetics*, 1993; 5: 338-343.
 59. Pericak-Vance MA; St George-Hyslop PH; Gaskell PC, Jr; Growdon J; Crain BJ; Hulette C; Gusella JF, Yamaoka L; Tanzi RE; Roses AD. Linkage analysis in familial Alzheimer disease: description of the Duke and Boston data set. *Genet. Epidemiol.*, 1993; 10: 361-364.
 60. Rogaev, EI, Lukiw WJ, Vaula G, Haines JL, Rogaeva EA, Tsuda T, Alexandrova N, Liang Y, Mortilla M, Amaducci L, Bergamini L, Bruni AC, Macciardi F, Montesi MP, Sorbi S, Rainero I, Pinessi L, Polinsky RJ, Frommelt P, Duara R, Lopez R, Pollen D, Gusella JF, Tanzi RE, Crapper-MacLachlan, St George-Hyslop PH. Analysis of the cFOS gene and the promotor of the amyloid precursor protein gene in familial Alzheimer's disease. *Neurology*, 1993; 43: 2275-2279.
 61. Bush AI, Pettingell, W, Paradis M, Tanzi RE. Modulation of A β adhesiveness and secretase site cleavage by zinc. *J. Biol. Chem.*, 1994; 269: 12152-12158.
 62. Slunt HH, Koch CV, Thinakaran G, Lo ACY, Tanzi RE, Sisodia SS. Expression of a ubiquitous, cross-reactive homologue of the mouse β -amyloid precursor protein (APP). *J. Biol. Chem.*, 1994; 269: 2637-2644.

63. Tanzi R, Gaston S, Bush A, Romano D, Pettingell W, Peppercorn J, Paradis M, Gurubhagavatula S, Jenkins B, Wasco W. Genetic heterogeneity of gene defects responsible for familial Alzheimer disease. *Genetica*, 1993, 91: 255-263 and in *Genetic and Evolution of Aging*, eds. Michael Rose and Caleb Finch, 1994; pp. 285-294.
64. Ali, G, Wasco W, Xingang C, Szabo P, Sheu K-F, Cooper A, Gaston SM, Gusella JF, Tanzi RE, Blass JP. Isolation, characterization, and mapping of the gene encoding the dihydrolipoyl succinyltransferase (E2k) of the human alpha-ketoglutarate dehydrogenase complex. *Som.Cell Mol. Genet.*, 1994; 20: 99-105.
65. Gregor P, Gaston SM, Yang X, O-Regan JP, Rosen DR, Tanzi RE, Patterson D, Haines JL, Horvitz HR, Uhl GR, Brown RH. Genetic and physical mapping of the GLUR5 glutamate receptor gene on human chromosome 21. *Hum. Genet.*, 1994; 94: 565-570.
66. Bush AI, Pettingell W, Multhaup G, Paradis MD, Vonsattel J-P, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A β amyloid formation by zinc. *Science*, 1994; 265: 1464-1467.
67. Bush AI, Pettingell WH, Paradis Md, Tanzi RE, Wasco W. The amyloid beta-protein precursor and its mammalian homologues. *J. Biol. Chem.*, 1994; 269: 26618-26621.
68. Muramatsu Y, Yamada T, Miura M, Sakai T, Suzuki Y, Serikawa T, Tanzi RE, Matsumoto Y. Wilson's disease gene is homologous to hts causing abnormal copper transport in Long-Evans Cinnamon Rats. *Gastroenterology*, 1994; 107: 1189-1192.
69. Cai X; Szabo P; Ali G; Tanzi RE; Blass JP. Pseudogene of dihydrolipoyl succinyltransferase (E2k) found by PCR amplification and direct sequencing of rodent-human cell hybrid DNAs. *Somat.Cell Mol. Genet.*, 1994; 20: 339-43.
70. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H,, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin J-F, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov Y, Pollen D, Wasco W, Haines JL, Da Silva R, Pericak-Vance M, , Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH. Cloning of a novel gene bearing mis-sense mutations in early onset familial Alzheimer disease. *Nature*, 1995; 375, 754-760.
71. Bush AI, Moir RD, Rosenkranz KM, Tanzi RE. Zinc and Alzheimer disease. *Science*, 1995; 268: 1920-1923.
72. Kim T-W, Wu K, Xu J-L, McAuliffe G, Tanzi RE, Wasco W, Black IB. Selective localization of amyloid precursor-like protein 1 in the cerebral cortex post-synaptic density. *Mol. Brain Res.*, 1995; 32: 36-44.
73. Kounnas MZ*, Moir RD*, Rebeck GW, Bush AI, Argaves WS, Hyman BT, Tanzi RE, Strickland DK. LDL receptor-related protein, a multifunctional apolipoprotein E receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. *Cell*, 1995; 82: 331-340. *shared first author

74. Levy-Lahad E*, Wasco W*, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu C, Jondro PD, Schmidt SD, Wang K, Crowley AC, Fu Y-H, Guenette SY, Galas D, Nemens E, Wijsman EM, Bird TD, Schellenberg GD, Tanzi RE. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science*, 1995; 269: 973-977. *shared first author
75. Kovacs DM, Wasco W, Witherby J, Felsenstein KM, Brunel F, Roeder RG, Tanzi RE. The upstream stimulatory factor functionally interacts with the Alzheimer amyloid β -protein precursor gene. *Hum. Mol. Genet.*, 1995; 9: 1527-1533.
76. Webster M-T, Groome N, Francis P, Pearce BR, Sherriff FE, Thinakaran G, Felsenstein KM, Wasco W, Tanzi RE, Bowen DM. A novel protein, amyloid precursor-like protein 2, present in human brain, cerebrospinal fluid and conditioned media. *Biochem. J.*, 1995; 310: 95-99.
77. Wasco W, Pettingell WP, Jondro JP, Schmidt SD, Gurubhagavatula S, Rodes L, DiBlasi T, Romano DM, Guenette SY, Kovacs DM, Growdon JH, Tanzi RE. Two novel mutations in the familial Alzheimer's disease gene on chromosome 14: Cys263Arg and Pro264Leu. *Nature Medicine*, 1995; 1: 848.
78. Corder EH, Saunders AM, Strittmatter WJ, Schmechel MD, Gaskell PC, Rimmler PA-C, Locke PA, Conneally PM, Schmechel KE, Tanzi RE, Gusella JF, Small GW, Roses AD, Pericak-Vance MA, Haines JL. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. *Neurology*, 1995; 45: 1323-1328.
79. Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE, Wasco W. Alzheimer - Associated Presenilins 1 and 2: Neuronal Expression in Brain and Localization to Intracellular Membranes in Mammalian Cells. *Nature Medicine*, 1996; 2: 224-230.
80. National Institute of Aging/Alzheimer's Association Working Group. Apolipoprotein E Genotyping in Alzheimer's Disease: Position Statement of the National Institute of Aging/Alzheimer's Association Working Group. *Lancet*, 1996; 347: 1091-1095.
81. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi RE, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nature Medicine*, 1996; 2: 864-870.
82. Irizarry MC, Kim T-W, McNamara M, Tanzi RE, George JM, Clayton DF, Hyman BT. Characterization of the precursor protein of the non-A β component of senile plaques in the human central nervous system. *J. Neuropath. Exp. Neurol.*, 1996; 55: 889-895.
83. Guenette SY, Chen J, Jondro PD, Tanzi RE. Association of a novel human FE65-like

protein with the cytoplasmic domain of the β -amyloid precursor protein. *Proc. Natl. Acad. Sci.*, 1996; 93: 10832-10837.

84. Cook DG, Sung JC, Golde TE, Felsenstein KM, Wojczk BS, Tanzi RE, Trojanowski JQ, V M-Y Lee, and Doms RW. Expression and analysis of presenilin 1 in a human neuronal system: Localization in cell bodies and dendrites. *Proc. Natl. Acad. Sci.*, 1996; 93: 9223-9228.
85. Berezsovsckaja O, Page K, Wasco W, Tanzi RE, Hyman BT. High Level Presenilin mRNA Expression During Development Parallels Notch Expression. *J. Neuropath. Exp. Neurol.*, 1997; 56: 40-44.
86. Page K, Hollister, Tanzi RE, Hyman BT. In Situ Hybridization of Presenilin 1 mRNA in Alzheimer's Disease and in Lesioned Rat Brain. *Proc. Natl. Acad. Sci. (U.S.A)*, 1996; 93: 14020-14024.
87. Tanzi RE. Neuropathology in the Down's Syndrome Brain. *Nature Medicine*, 1996; 2: 31-32.
88. Tanzi RE, Kovacs DM, Kim T-W, Moir RD, Guenette SY, Wasco W. The Gene Defects Responsible for Familial Alzheimer's Disease. *Neurobiology of Disease*, 1996; 3: 159-168.
89. Blacker D, Haines JL, Rodes L, Terwedow H, Go R, Harrell L, Perry R, Bassett SS, Chase G, Meyers D, Albert M, Tanzi RE. APOE-4 and Age of Onset of Alzheimer's Disease: The NIMH Genetics Initiative. *Neurology*, 1997; 48: 139-147.
90. Kim T-W, Hallmark O.G., Pettingell W.H., Wasco W., Tanzi R.E. Endoproteolytic Cleavage and Proteasomal Degradation of Presenilin 2 in Transfected Cells. *J. Biol. Chem.*, 1997; 272: 11006-11010.
91. Kim T-W, Pettingell WH, Jung YK, ,Kovacs DM, Tanzi RE. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. *Science*, 1997; 277:, 373-376.
92. Gomez-Isla T., Wasco W., Pettingell W.P., Gurubhagavatula S, Schmidt S.D., Jondro P.D., McNamara M., Rodes L.A., DiBlasi T., Growdon W.B., Seubert P., Schenk D., Growdon J.H., Hyman B.T., Tanzi R.E. Novel Presenilin 1 Gene Mutation: Increased β -Amyloid and Neurofibrillary Changes. *Annals of Neurology*, 1997; 41: 809-813.
93. Seeger M., Norstedt C., Petanceska S., Kovacs D.M., Gouras G.K., Hahne S. Fraser P., Levesque L., Czernik A.J., St George-Hyslop P., Sisodia S.S., Thinakaran G., Tanzi R.E., Greengard P., Gandy S. (1997) Evidence for Phosphorylation and Oligomeric Assembly of Presenilin 1., *Proc. Natl. Acad. Sci. (USA)*, 1997; 94: 5090-5094.
94. Suzuki T., Ando K., Isohara T., Oishi M., Lim G.S., Satoh Y., Wasco W., Tanzi R.E., Nairn A.C., Greengard P., Gandy S.E., Kirino Y. Phosphorylation of Alzheimer's β -amyloid precursor-like proteins. *Biochemistry*, 1997; 36: 4643-4649.

95. Huang X., Atwood CS, Moir RD, Hartshorn MA, Vonsattel J-P, Tanzi RE, Bush AI. Zinc-Induced Alzheimer's A β 1-40 Aggregation is Mediated by Conformational Factors. *J. Biol. Chem.*, 1997; 272:26464-26470.
96. The APOE and Alzheimer Disease Meta Analysis Consortium. Effects of Age, Gender, and Ethnicity on the Association between Apolipoprotein E Genotype and Alzheimer Disease. *JAMA*, 1997; 278: 1349-1356.
97. Moir RD, Lynch T, Bush AI, Whyte S, Henry A, Potbury S, Multhaup G, Small DH, Tanzi RE, Beyreuther K, Masters CL. Relative Increase in Alzheimer's Disease of Soluble Forms of Cerebral A β Amyloid Protein Precursor Containing the Kunitz Protease Inhibitory Domain. *J. Biol. Chem.* 1998; 273: 5013-5019.
98. Hock C, Golombowski S, Muller-Spahn F, Naser W, Beyreuther K, Monning U, Schenk D, Vigo-Pelfrey C, Bush AI, Moir R, Tanzi RE, Growdon JH, Nitsch RM. Cerebrospinal fluid levels of amyloid precursor protein and amyloid β -peptide in Alzheimer's disease and major depression-inverse correlation with dementia severity. *Eur. Neurol.* 1998; 39: 111-118.
99. Atwood C.S., Moir R.D., Huang X., Bacarra M.E., Scarpa R.C., Romano D.M., Hartshorn M.A., Tanzi R.E., Bush A.I. Dramatic aggregation of Alzheimer A β by Cu(II) is induced by conditions representing physiological acidosis. *J. Biol. Chem.*, 1998; 273: 12817-12826.
100. Blacker D., Wilcox M.A., Laird N.M., Rodes L., Horvath S.M., Go R.C.P., Perry R., Watson B., Bassett S.S., McInnis M.G., Albert M.S., Hyman B.T., Tanzi R.E. Alpha-2-macroglobulin is genetically associated with Alzheimer's disease. *Nature Genetics*, 1998; 19: 357-360.
101. Xia M, Berezovska O, Kim T-W, Xia W, Liao A, Tanzi RE, Selkoe DJ, Hyman BT. Lack of specific association of Presenilin 1 (PS-1) protein with plaques and tangles in Alzheimer's disease. *J. Neur. Res.* 1998; 158: 15-23.
102. Etcheberrigaray R, Hirashima N, Nee L, Prince J, Govoni S, Racchi M, Tanzi RE, Alkon DL. Calcium Responses in Fibroblasts from Asymptomatic Members of Alzheimer's Disease Families. *Neurobiology of Disease*, 1998; 5: 37-45.
103. McNamara M.J., Ruff C.T., Wasco W., Tanzi R.E., Thinakaran G., Hyman B.T. Immunohistochemical and in situ analysis of amyloid precursor-like protein 1 and amyloid precursor-like protein 2 expression in Alzheimer disease and aged control brains. *Brain Res.*, 1998; 804: 45-51.
104. Liao A., Nitsch R.M., Greenberg S., Blacker D., Albert M., Rebeck G.W., Gomez-Isla T., Clatworthy A., Binetti G., Hock C., Finckh U., Mueller-Thomsen T., Mann U., Zuchowski K., Besiegel U., Stadlin H., Growdon J.H., Tanzi R.E., Hyman B.T. Genetic association of an alpha-2-macroglobulin polymorphism and Alzheimer's disease. *Hum. Mol. Genet.*, 1998; 7: 1953-1956.

105. Tesco G., Kim T.-W., Diehlmann A., Beyreuther K., Tanzi R.E. Abrogation of the presenilin 1/ β -catenin interaction and preservation of the heterodimeric presenilin 1 complex following caspase activation. *J. Biol. Chem.*, 1998; 273: 33909-33921.
106. Moir R.D., Atwood C.S., Romano D.M., Laurans M.H., Huang X., Bush A.I., Smith J.D., Tanzi R.E. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A β using physiological concentrations. *Biochemistry*, 1999; 38: 4595-4603.
107. Guenette S.Y., Chen J., Ferland A. Tanzi R.E. hFE65L influences APP maturation and secretion. *J. Neurochem.*, 1999; 73: 985-993.
108. Blacker D., Crystal A.S., Wilcox M.A., Laird N.M., Tanzi R.E. Alpha2-macroglobulin gene and Alzheimer's disease. *Nature Genetics*, 1999; 22: 16-17.
109. Chemy RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, Tanzi RE, Masters CL, Bush AI. Aqueous dissolution of Alzheimer's disease A β amyloid deposits by biometal depletion. *J. Biol. Chem.*, 1999; 274: 23223-23228.
110. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Stokes K, Cuajungco MP, Moir RD, Glabe C, Tyndall J, Hanson GR, Beyreuther K, Masters CL, Bowden EF, Fairlie DP, Tanzi RE, Bush AI. The Alzheimer's disease A β peptide directly generates hydrogen peroxide through metal ion reduction. *Biochem.*, 1999; 38: 7609-7616.
111. Chan C-W, Dharmarajan A, Atwood CS, Huang X, Tanzi RE, Bush AI, Martins RN. Anti-apoptotic action of Alzheimer A β . *Alzheimer's Reports* 1999; 2: 1-6.
112. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI. Cu(II) potentiation of alzheimer A-beta neurotoxicity: Correlation with cell-free hydrogen peroxide production and metal reduction. *J Biol. Chem.* 1999; 4: 7111-7116.
113. Kovacs DM, Mancini R, Henderson J. Na SJ, Kim T-W, Tanzi RE. Staurosporine-induced activation of caspase-3 is potentiated by presenilin 1 FAD mutations in human neuroglioma cells. *J. Neurochem.*, 1999; 73: 2278-2285.
114. Saunders A.J., Kim T.-W., Tanzi R.E. BACE maps to chromosome 11 and a BACE homolog BACE2, resides in the obligate Down syndrome region of chromosome 21. *Science*, 1999, 286: 1255-1256a.
115. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. *Ann Neurol*, 2000, 47: 430-439.
116. Pack-Chung E, Meyers MB, Pettingell WP, Moir RD, Brownawell AM, Cheng I, Tanzi RE, Kim T-W. Presenilin 2 Interacts with Sorcin, a Modulator of the Ryanodine Receptor. *J. Biol. Chem.*, 2000; 275: 14440-14445.

117. Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, Strickland DK. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. *J. Biol. Chem.*, 2000; 10: 7410-7415.
118. Abbenante G, Kovacs DM, Leung DL, Craik DJ, Tanzi RE, Fairlie DP. Inhibitors of beta-amyloid formation based on the beta-secretase cleavage site. *Biochem. Biophys. Res. Commun.* 2000; 268: 133-135.
119. Goldstein L.E., Hartshorn M., Leopold M., Huang X, Atwood C.S., Saunders A.J., Lim J, Scarpa R.C., Bowden E.F., Tanzi R.E., Bush A.I. 2-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote γ -crystallin polymerization through metal ion reduction. *Biochem.* 2000; 39: 7266-75.
120. Atwood CS, Huang X, Khatri A, Scarpa RC, Kim YS, Moir RD, Tanzi RE, Roher AE, Bush AI. Copper catalyzed oxidation of Alzheimer's A β . *Cell Mol Biol* 2000 46: 777-783.
121. Sawamura N, Morishima-Kawashima M, Waki H, Kobayashi K, Kuramochi T, Frosch MP, Ding K, Ito M, Kim TW, Tanzi RE, Oyama F, Tabira T, Ando S, Ihara Y. Mutant-presenilin 2-transgenic mice: A large increase in the levels of A β 42 is presumably associated with the low-density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. *J Biol Chem.* 2000, 275: 27901-27908.
122. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis M, Go R, Vekrellis K, Selkoe D, Saunders A, Tanzi R. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. *Science* 2000 290: 2302-2303.
123. Bertram L, Blacker D, Crystal A, Mullin K, Keeney D, Jones J, Basu S, Yhu S, Guenette S, McInnis M, Go R, Tanzi R. Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies. *Exp. Gerontol.* 2000 35: 1353-1361.
124. Yoo AS, Cheng I, Chung S, Grenfell TZ, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, Saunders AJ, Ding K, Frosch MP, Tanzi RE, and Kim T-W. Presenilin-mediated modulation of capacitative calcium entry. *Neuron* 2000; 27: 561-572.
125. Collins JS, Perry RT, Watson B Jr, Harrell LE, Acton RT, Blacker D, Albert MS, Tanzi RE, Bassett SS, McInnis MG, Campbell RD, Go RC. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer disease genetics initiative. *Am J Med Genet.* 2000 96: 823-30.
126. Liu Y, Jones M, Hingtgen CM, Bu G, Larabee N, Tanzi RE, Moir RD, Nath A, He JJ. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. *Nature Medicine* 2000 12:1380-1387.
127. Guenette SY, Bertram L, Crystal A, Bakondi B, Hyman BT, Rebeck GW, Tanzi RE, Blacker D. Evidence against association of the FE65 gene (APBB1) intron 13

- polymorphism in Alzheimer's patients. *Neurosci Lett.* 2000 296:17-20.
128. Buxbaum JD, Lilliehook C, Chan JY, Go RC, Bassett SS, Tanzi RE, Wasco W, Blacker D. Genomic structure, expression pattern, and chromosomal localization of the human calsenilin gene: no association between an exonic polymorphism and Alzheimer's disease. *Neurosci Lett.* 2000 294: 135-138.
 129. Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li QX, McLean CA, Multhaup G, Beyreuther K, Tanzi RE, Masters CL, Bush AI. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. *J Struct Biol.* 2000 130: 209-216.
 130. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper-binding site on amyloid beta1-42. *J Neurochem.* 2000 75: 1219-33.
 131. Bertram L, Guénette S., Jones J, Keeney D, Mullin K, Basu S, Yhu S, Deng A, Rebeck GW, Hyman BT, Go R, McInnis M, Blacker D, Tanzi R. No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer's disease. *Ann. Neurol.* 2001;49: 114-116.
 132. Cherny RA, Atwood CS, Xilinas X, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y-S, Huang X, Goldstein LE, Moir RD, Lim JT, Zheng H, Beyreuther K, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits β -amyloid accumulation in Alzheimer's disease transgenic mice. *Neuron*, 2001; 30: 665-676.
 133. Kim JW, Chang T-S, Lee JE, Huh S-H, Yeon SW, Yang WS, Joe CO, Mook-Jung I, Tanzi RE, Kim T-W, Choi E-J. Negative Regulation of the SAPK/JNK signaling pathway by Presenilin 1. *J. Cell Biol.* 2001; 153: 457-463.
 134. Geschwind DH, Sowinski J, Lord, C, Iversen P, Shestack J, Jones P., Ducat L, Spence S., and the AGRE Steering Committee. The Autism Genetic Resource Exchange: A Resource fore the Study of Autism and Related Neuropsychiatric Conditions. *Am. J. Hum. Genet.* 2001 69: 463-466.
 135. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, L Dawson V, Dawson TM, Ross CA. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. *Hum Mol Genet.* 2001; 10: 919-926.
 136. Rebeck GW, Moir RD, Mui S, Strickland DK, Tanzi RE, Hyman BT. Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. *Brain Res Mol Brain Res.* 2001; 5: 238-245.
 137. Liu J., Nyholt DR, Magnussen P., Parano P., Geschwind D., Lord C, Iversen P., Hoh J., Ott J., Gill C., et al. A genome-wide screen for autism susceptibility loci. *Am. J. Hum.*

- Genet. 2001 69: 327-340.
138. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. *Nat Cell Biol.* 2001; 10:905-912
 139. Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. *J. Int. Neuropsychol. Soc.* 2001 7: 631-9.
 140. Alarcon M., Cantor RM, Liu J, Gillian C, Geschwind DH et al. Evidence for a language quantitative trait locus on chromosome 7q in multiplex autism families. *Am. J. Hum. Genet.* 2002 70: 60-71.
 141. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, Tanzi R, Jones K, Albert MS. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. *Neurology.* 2002 58:1188-1196.
 142. Goto, J., Tanzi, RE. The Role of the Low-Density Lipoprotein Receptor-Related Protein (LRP1) In Alzheimer's A β Generation: Development of a Cell-Based Model System. *J Mol Neurosci* 2002 19:37-41.
 143. Rogers J, Randall J, Eder P, Huang X, Bush A, Tanzi R, Venti A, Peyton S, Giordano A, Greig N, Satinder S, Gullans S. Alzheimer's disease drug discovery targeted to the APP mRNA 5' untranslated region. *J. Mol. Neurosci.*, 2002 19:77-82.
 144. Rogers J, Randall J, Cahill C, Eder P, Huang X, Gunshin H, Leiter L, McPhee JH., Satinder S, Utsuki T, Greig N, Tanzi R, Bush A, Giordano A, Gullans S. An Iron-responsive Element Type II in the 5' untranslated region of the Alzheimer's Amyloid Precursor Protein Transcript. *J. Biol. Chem.*, 2002 277: 45518-28.
 145. Guénette SY, Chang Y, Hyman BT, Tanzi RE, Rebeck GW. LRP protein levels and endocytic function are reduced by overexpression of the FE65 adaptor protein, FE65L1. *J. Neurochem.* 2002 82: 755-762.
 146. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, Bush AI. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H₂O₂. *J. Biol. Chem.*, 2002 277:40302-8.
 147. Bertram L, Saunders A, Mullin K, Sampson, A, Moscarillo TJ, Bassett SS, Go RCP, Blacker D, Tanzi RE. No association between marker *D10S1423* and Alzheimer's disease. *Molecular Psychiatry*, 2003, 6: 571-573.
 148. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi RE. Results of a high-resolution genome screen of 437 Alzheimer's Disease families. *Hum. Mol. Genet.*, 2003 12: 23-32.

149. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Bush AI. Cytosolic β -amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. *Lancet* 2003 361: 1258–65
150. Farris W, Chang Y, Mansourian S, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guénette S. Insulin-Degrading Enzyme Regulates the Levels of Insulin, Amyloid β -protein and the APP Intracellular Domain *In Vivo*. *Proc. Natl. Acad. Sci. (USA)* 2003; 100: 4162-7.
151. Saunders AJ, Bertram L, Mullin K, Sampson AJ, Basu S, Jones J, Kinney D, MacKenzie-Ingano, LM, Yu S, Albert, MS, Moscarillo TJ, Go R, Bassett S, PhD⁵, Daly MJ, Laird NM, Wang G, Velicelebi G, Wagner SL, Becker DK, Tanzi RE, Blacker D. Genetic Association of Alzheimer's Disease with Multiple Polymorphisms in Alpha-2-Macroglobulin. *Hum. Mol. Genet.* 2003, 12: 2765-2776.
152. Xie Z, Moir RD, Romano DM, Tesco G, Kovacs DM, Tanzi RE Hypocapnia Induces Caspase-3 Activation and Increases A β Production. *Neurodegenerative Diseases*, 2004, 1: 29 – 37.
153. Tesco G, Koh YH, Tanzi RE Caspase activation increases A β generation independently of caspase cleavage of APP. *J. Biol. Chem.*, 2003, 278: 46074-46080.
154. Chang Y, Tesco G, Jeong WJ, Lindsley L, Eckman EA, Eckman CB, Tanzi RE, Guénette SY γ -secretase processing of APP C-terminal fragments is enhanced by FE65L1 binding and results in increased generation of A β and AICD at or near the cell surface. *J. Biol. Chem.*, 2003 278:51100-51107.
155. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li Q-X, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A-beta amyloid deposition and toxicity in Alzheimer's disease: A pilot phase 2 clinical trial. *Arch. Neurol.*, 2003 60: 1685-1691.
156. Perry RT, Wiener H, Harrell LE, Blacker D, Tanzi RE, McInnis M, Bassett SS, Go RCP. Association of polymorphisms in MTHFR and TGF beta 1 in Alzheimer's disease patients. *Am. J. Hum. Genet.* 2003 73: 471-471.
157. Bertram, L, Menon, R, Mullin, K, Parkinson M, Bradley ML, Blacker D, Tanzi RE *PEN2* is not a genetic risk factor for Alzheimer's disease in a large family sample. *Neurology*, 2004, 62:304-306.
158. Farris W, Mansourian S, Leissring MA, Bertram L, Eckman EA, Eckman CB, Tanzi RE, Selkoe DJ Diabetes-Inducing Mutations in Insulin-Degrading Enzyme Cause Impaired Degradation of Neuronal Amyloid β -Protein. *Am. J. Pathol.*, 2004, 164:1425-34.
159. Bertram L, Parkinson M, Mullin K, Menon R, Blacker D, Tanzi RE. No association

- between a previously reported OLR1 3'UTR polymorphism and Alzheimer's disease in a large family sample. *J. Med. Genet* 2004, 41:286-288.
160. Nagano S, Huang X, Moir RD, Payton SM, Tanzi RE, Bush AI. Peroxidase activity of COX-2 cross-links A β and generates A β : COX-2 hetero-oligomers are increased in Alzheimer's disease. *J. Biol. Chem.*, 2004, 279:14673-14678.
 161. Xie Z, Romano DM, Kovacs DM, Tanzi RE. Effects of RNAi-mediated silencing of γ -secretase complex components on cell sensitivity to caspase activation. *J. Biol. Chem.*, 2004, 279:34130-34137.
 162. Cherny RA, Barnham K, Lynch T, Volitakis I, Li Q-X, McLean CA, Multhaup G, Beyreuther K, Tanzi RE, Masters CL, Bush AI. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. *J. Struct Biol* 2000; 130:209-216.
 163. Xie Z, Romano DM, Tanzi RE. Effects of RNAi-Mediated Silencing of PEN-2, APH-1a, and Nicastrin on Wild-Type Versus FAD Mutant Forms of Presenilin 1. *J. Mol. Neurosci.*, 2005; 25:67-78.
 164. Bertram L, Hsiao M, Mullin K, Parkinson M, Menon R, Moscarillo TJ, Blacker D, Tanzi RE. ACAT1 is not associated with Alzheimer's disease in two independent family-based samples. *Mol. Psych.*, 2005 10: 522-524.
 165. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's A β peptides. *J Biol Inorg Chem.* 2004 8:954-960.
 166. Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremsky JN, Lai L, Li X, Moir RD, Tanzi RE, Bush AI, Kowall NW, Rogers JT, Huang X. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. *Exp Gerontol.* 2004 11:1641-9.
 167. Xie Z, Romano DM, Tanzi RE. RNAi-mediated silencing of X11 α and X11 β attenuate A β levels via differential effects on APP processing. *J. Biol. Chem.*, 2005; 280:15413-15421.
 168. Moir RD, Tanzi RE. LRP-mediated clearance of A β is inhibited by KPI-containing isoforms of APP. *Curr. Alzh. Res.*, 2005 2: 269-273.
 169. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C, Ramasamy K, Mullin K, Menon R, Sampson AJ, Hsiao MY, Elliott KJ, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D, Tanzi RE. Family-based association between Alzheimer's disease and variants in *UBQLN1*. *New Engl. J. Med.*, 2005 352: 884-894.
 170. Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi. Autoantibodies to redox-modified oligomeric A β are attenuated in the plasma of AD patients. *J. Biol. Chem.*, 2005; 280:17458-17463.

171. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sperling RA. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. *Neurology*, 2005; 65:404-411.
172. Tesco G, Ginestroni A, Hiltunen M, Kim M, Dolios G, Hyman BT, Wang R, Berezovska O, Tanzi RE. APP substitutions V715F and L720P alter PS1 conformation and differentially affect A β and AICD generation. *J Neurochem.*, 2005; 95:446-456.
173. Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G. BACE is degraded via the lysosomal pathway. *J Biol Chem.*, 2005; 280:32499-32504.
174. Bertram L, Tanzi RE. The ubiquilin 1 gene and Alzheimer's Disease (Author's Reply). *N Engl J Med.* 2005, 352: 2752-2753.
175. Bertram L, Parkinson M, McQueen MB, Mullin K, Hsiao M, Menon R, Moscarillo TJ, Blacker D, Tanzi RE. Further evidence for LBP-1c/CP2/LSF association in Alzheimer's disease families. *J Med Genet.* 2005; 42:857-862.
176. Bertram L, Hsiao M, Mullin K, Parkinson M, Menon R, Moscarillo TJ, Blacker D, Tanzi RE. ACAT1 is not associated with Alzheimer's disease in two independent family-based samples. *Mol Psychiatry.* 2005; 10:522-524.
177. Xie Z, Dong, Y, Maeda U, Alfile P, Culley DJ, Crosby G, Tanzi RE. The common inhalation anesthetic isoflurane induces apoptosis and increases A β levels. *Anesthesiology* 2006; 104:988-994.
178. Culley DJ, Yukhananov RY, Xie Z., Galli R, Tanzi RE, Crosby G. Hippocampal gene expression is altered 48 h after general anesthesia in aged rats. *Eur J Pharm*, 2006; 7; 549(1-3):71-78.
179. Romano, DM., Dong, Y., Hiltunen, M. Tanzi, RE. Xie, Z. Artefactual effects of lipid cell transfection reagents on APP processing and A β production. *Amyloid-The Journal of Protein Folding Disorders*, 2006; 13:86-92.
180. Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, Peng Z, Tanzi RE, Rogers JT, Huang X. Metal exposure and Alzheimer's pathogenesis. *J Struct Biol*, 2006; 155:45-51.
181. Bertram L, Hsiao M, Lange C, Blacker D, Tanzi RE. Single-Nucleotide Polymorphism rs498055 on Chromosome 10q24 Is Not Associated with Alzheimer Disease in Two Independent Family Samples. *Am J Hum Genet*, 2006; 79:180-183.
182. The Huntington Study Group PHAROS Investigators. At Risk for Huntington Disease: The PHAROS (Prospective Huntington At Risk Observational Study) Cohort Enrolled. *Arch Neurol*, 2006; 63:991-998.

183. Hiltunen M, Lu A, Thomas AV, Romano DM, Kim M, Jones PB, Xie Z, Kounnas MZ, Wagner SL, Berezovska O, Hyman BT, Tesco G, Bertram L, Tanzi RE. Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion. *J Biol Chem*. 2006; 281:32240-53.
184. Thomas AV, Herl L, Spoelgen R, Hiltunen M, Jones PB, Tanzi RE, Hyman BT, Berezovska O. Interaction between presenilin 1 and ubiquilin 1 as detected by fluorescence lifetime imaging microscopy and a high throughput fluorescent plate reader. *J Biol Chem*, 2006; 281:281:26400-7.
185. Xie Z, Dong Y, Maeda U, Moir R, Inouye SK, Culley DJ, Crosby G, Tanzi RE. Isoflurane-induced apoptosis: a potential pathogenic link between delirium and dementia. *J Gerontol A Biol Sci Med Sci*, 2006; 12:1300-1306.
186. Perry RT, Wiener H, Harrell LE, Blacker D, Tanzi RE, Bertram L, Bassett SS, Go RC. Follow-up mapping supports the evidence for linkage in the candidate region at 9q22 in the NIMH Alzheimer's disease Genetics Initiative cohort. *Am J Med Genet B Neuropsychiatr Genet*. 2007; 144:220-7.
187. Xie Z, Dong Y, Maeda U, Xia W, Tanzi RE. RNA interference silencing of the adaptor molecules ShcC and fe65 differentially affect amyloid precursor protein processing and A β generation. *J Biol Chem*, 2007; 282:4318-25.
188. Bertram, L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic Meta-Analyses of Alzheimer's Disease Genetic Association Studies: The AlzGene Database. *Nature Genetics*, 2007; 39:17-23.
189. Bertram L, Mullin K, Parkinson M, Hsiao M, Moscarillo TJ, Wagner SL, Becker KD, Velicelebi G, Blacker D, Tanzi RE. Is alpha-T catenin (VR22) an Alzheimer's disease risk gene? *J Med Genet*, 2007; 44:e63.
190. McQueen MB, Bertram L, Lange C, Becker KD, Albert MS, Tanzi RE, Blacker D. Exploring Candidate Gene Associations with Neuropsychological Performance. *Am J Med Genet B Neuropsychiatr Genet*, 2007; 144(8):987-91.
191. Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE. Decreased catalytic activity of the insulin degrading enzyme in chromosome 10-linked Alzheimer's disease families. *J Biol Chem*, 2007; 282(11):7825-32.
192. Bertram L, Hsiao M, McQueen MB, Parkinson M, Mullin K, Blacker D, Tanzi RE. The *LDLR* Locus in Alzheimer's disease: A Family-based Study and Meta-Analysis of Case-Control Data. *Neurobiology of Aging*, 2007; 28(1):18.e1-4.
193. Xie Z, Dong Y, Maeda U, Moir R, Xia W, Culley DJ, Crosby G, Tanzi RE. The Inhalation

Anaesthetic Isoflurane Induces a Vicious Cycle of Apoptosis and A β Accumulation. *J. Neurosci.*, 2007; 27:1247-1254.

194. The Autism Genome Project Consortium; Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu XQ, Vincent JB, Skaug JL, Thompson AP, Senman L, Feuk L, Qian C, Bryson SE, Jones MB, Marshall CR, Scherer SW, Vieland VJ, Bartlett C, Mangin LV, Goedken R, Segre A, Pericak-Vance MA, Cuccaro ML, Gilbert JR, Wright HH, Abramson RK, Betancur C, Bourgeron T, Gillberg C, Leboyer M, Buxbaum JD, Davis KL, Hollander E, Silverman JM, Hallmayer J, Lotspeich L, Sutcliffe JS, Haines JL, Folstein SE, Piven J, Wassink TH, Sheffield V, Geschwind DH, Bucan M, Brown WT, Cantor RM, Constantino JN, Gilliam TC, Herbert M, Lajonchere C, Ledbetter DH, Lese-Martin C, Miller J, Nelson S, Samango-Sprouse CA, Spence S, State M, Tanzi RE, Coon H, Dawson G, Devlin B, Estes A, Flodman P, Klei L, McMahon WM, Minshew N, Munson J, Korvatska E, Rodier PM, Schellenberg GD, Smith M, Spence MA, Stodgell C, Tepper PG, Wijsman EM, Yu CE, Roge B, Mantoulan C, Wittmeyer K, Poustka A, Felder B, Klauck SM, Schuster C, Poustka F, Bolte S, Feineis-Matthews S, Herbrecht E, Schmotzer G, Tsiantis J, Papanikolaou K, Maestrini E, Bacchelli E, Blasi F, Carone S, Toma C, Van Engeland H, de Jonge M, Kemner C, Koop F, Langemeijer M, Hijimans C, Staal WG, Baird G, Bolton PF, Rutter ML, Weisblatt E, Green J, Aldred C, Wilkinson JA, Pickles A, Le Couteur A, Berney T, McConachie H, Bailey AJ, Francis K, Honeyman G, Hutchinson A, Parr JR, Wallace S, Monaco AP, Barnby G, Kobayashi K, Lamb JA, Sousa I, Sykes N, Cook EH, Guter SJ, Leventhal BL, Salt J, Lord C, Corsello C, Hus V, Weeks DE, Volkmar F, Tauber M, Fombonne E, Shih A.. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. *Nature Genetics*, 2007; 39:319-328.
195. Friedlich AL, Tanzi RE, Rogers JT. The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. *Mol Psychiatry*, 2007; 12:222-223.
196. Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. *Arch Neurol.*, 2007; Jun;64(6):862-71.
197. Albert M, Blacker D, Moss MB, Tanzi R, McArdle JJ. Longitudinal change in cognitive performance among individuals with mild cognitive impairment. *Neuropsychology*, 2007; 21(2):158-69.
198. Vepsalainen S, Parkinson M, Helisalml S, Mannermaa A, Soininen H, Tanzi R, Bertram L, Hiltunen M. Insulin degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. *J Med Genet.*, 2007; 44(9):606-8.
199. Tesco G, Koh YH, Kang E, Cameron A, Das S, Sena-Esteves M, Hiltunen, Yang S-H, Zhong Z, Shen Y, Simpkins J, Tanzi RE. Depletion of GGA3 stabilizes BACE and enhances β -secretase activity. *Neuron*, 2007; 54(5):721-37.
200. Li A, Xie Z, Dong Y, McKay KM, McKee ML, Tanzi RE. Isolation and characterization

of the *Drosophila* ubiquilin ortholog dUbqln: In vivo interaction with early-onset Alzheimer disease genes. *Hum Mol Genet.*, 2007; 16(21):2626-39.

201. Huttunen HJ, Guenette SY, Peach C, Greco C, Xia W, Kim DY, Barren C, Tanzi RE, Kovacs DM. Htra2 regulates APP metabolism through endoplasmic reticulum-associated degradation. *J. Biol Chem.* 2007; 282(38):28285-95.
202. Hamshere ML, Holmans PA, Avramopoulos D, Bassett SS, Blacker D, Bertram L, Wiener H, Rochberg N, Tanzi RE, Myers A, Wavrant-De Vrieze F, Go R, Fallin D, Lovestone S, Hardy J, Goate A, O'donovan M, Williams J, Owen MJ. Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's Disease. *Hum Mol Genet.* 2007 2007; 16(22):2703-12.
203. Zhang C, Khandelwal PJ, Chakraborty R, Cuellar TL, Sarangi S, Patel SA, Cosentino CP, O'connor M, Lee JC, Tanzi RE, Saunders AJ. An AICD-based Functional Screen to Identify APP Metabolism Regulators. *Mol Neurodegener.* 2007; 2(1):15
204. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E, Stefansson H, Ferreira MAR, Green T, Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, Gusella JF, Sklar P, Wu, B-L, Daly MJ, for the Autism Consortium. Association between Microdeletion and Microduplication at 16p11.2 and Autism. *N Engl J Med*, 2008; 358:667-75.
205. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, Tanzi RE, Albert, MS, Greenberg SM, Guttmann CRG, Magnetic Resonance Imaging White Matter Hyperintensities and Brain Volume in the Prediction of Mild Cognitive Impairment and Dementia. *Arch Neurol.* 2008; 65(1):94-100.
206. Zhang B, Dong Y, Zhang G, Moir RD, Xia W, Yue Y, Tian M, Culley DJ, Crosby G, Tanzi RE, Xie Z. The inhalation anesthetic desflurane induces caspase activation and increases amyloid-beta protein levels under hypoxic conditions. *J Biol Chem.* 2008; 283(18):11866-75.
207. Zhang G, Dong Y, Zhang B, Ichinose F, Wu X, Culley DJ, Crosby G, Tanzi RE, Xie Z. Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine. *J Neurosci.* 2008; 28:4551-60.
208. Allen NC, Bagade S, McQueen MB, Ioannidis JPA, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the szGene database. *Nature Genetics* 2008; 40:827-834.
209. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Huggins P, Parsons J, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Loughton K, Li Q-X, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Cappai R, Ritchie CW, Tanzi RE, Masters CL, Barnham KJ, Bush AI. Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial A β . *Neuron*

2008; 59:43–55.

210. Kavvoura FK, McQueen MP, Khoury MJ, Tanzi RE, Bertram L, Ioannidis JPA. Evaluation of the potential excess of statistically significant findings in reported genetic association studies: application to Alzheimer's disease. *Am. J. Epidemiol.* 2008; 168:855-865.
211. Fardo D, Bertram L, Dalila P, Lazarus R, Becker, Manolio T, O'Donnell C, Neale B, Lasky-Su, J, Daly M, Faraone S, Scherer S, Weiss S, Tanzi R, Lange C. Using transmission rates in family-based genome-wide association studies to estimate platform-specific genotyping errors that cannot be detected by standard quality control filtering. *A. J. Epidemiol.* 2008; In Press.
212. Schaffer BAJ, Bertram L, Miller BL, Mullin K, Weintraub S, Johnson N, Bigio EH, Mesulam M, Wiedau-Pazos M, Jackson GR, Cummings JL, Cantor RL, Levey AI, Tanzi RE, Geschwind DH. Association of GSK3B with Alzheimer's Disease and Frontotemporal Dementia. *Archives Neurol.* 2008; 65:1368-1374.
213. Lee IH, Culley DJ, Baxter MG, Xie Z, Tanzi RE, Crosby G. Spatial memory is intact in aged rats after propofol anesthesia. *Anesth. Analg.* 2008; 107:1211-1215.
214. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, DiVito J, Ionita L, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to *APOE*. *Am. J. Hum. Genet.* 2008; 83:623-632.
215. Lu A, Hiltunen M, Romano DM, Soininen H, Hyman BT, Bertram L, Tanzi RE. Effects of Ubiquilin 1 on the Unfolded Protein Response. *J Mol Neurosci.* 2008; In Press
216. Cotton RGH, Auerbach AD, Axton M, Barash C, Berkovic SF, Brookes AJ, Burn J, Cutting G, den Dunnen JT, Flicek P, Freimer N, Greenblatt MS, Howard HJ, Katz M, Macrae FA, Maglott D, Möslein G, Povey S, Ramesar RS, Richards CS, Seminara D, Smith TD, Sobrido M-J, Solbakk JH, Tanzi RE, Tavtigian SV, Taylor GR, Utsunomiya J, Watson M. The Human Variome Project. *Science* 2008; 322:861-862.
217. Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R; National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group. Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci. *Arch Neurol.* 2008; 65:1518-1526.
218. Bertram L, Schjeide BM, Hooli B, Mullin K, Hiltunen M, Soininen H, Ingelsson M, Lannfelt L, Blacker D, Tanzi RE. No association between CALHM1 and Alzheimer's disease risk. *Cell* 2008; 135:993-994.

219. Xie Z, Culley DJ, Dong Y, Zhang G, Zhang B, Moir RD, Frosch MP, Crosby G, Tanzi RE. The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein levels in vivo. *Ann Neurol*. 2008; 64:618-627.
220. Myre MA, Washicosky K, Moir RD, Tesco G, Tanzi RE, Wasco W. Reduced amyloidogenic processing of the amyloid beta-protein precursor by the small-molecule Differentiation Inducing Factor-1. *Cell Signal*. 2009; 21:567-76.
221. Schjeide, B.-M.M., Hooli, B., Parkinson, M., Hogan, M.F., Divito, J., Mullin, K., Blacker, D., Tanzi, R., and Bertram, L. Follow-up of genome-wide association results suggests GAB2 as an Alzheimer's disease susceptibility gene. *Arch. Neurol*. 2009; 66:250-254.
222. Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, Parkinson M, Lange C, Blacker D, Tanzi RE, Bertram L. Assessment of Alzheimer's disease case-control associations using family-based methods. *Neurogenetics* 2009; 10:19-25.
223. Pihlajamäki M, Miller SL, DePeau KM, Celone KA, Bertram L, Tanzi RE, Dickerson BC, Albert MS, Blacker D, Sperling RA. Apolipoprotein E ϵ 4 disrupts fMRI deactivation in normal aging and Alzheimer's disease. *Brain*, 2009; In Press.
224. Dong Y, Zhang G, Zhang B, Moir RD, Xia W, Marcantonio ER, Culley DJ, Crosby G, Tanzi RE, Xie Z. The common inhalational anesthetic sevoflurane induces apoptosis and increases A β levels. *Archives of Neurology*, 2009; 66(5):620-31.
225. Kim M, Suh J, Romano D, Truong MH, Mullin K, Hooli B, Norton D, Tesco G, Elliott K, Wagner SL, Moir RD, Becker KD, Tanzi RE. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. *Hum Mol Genet*. 2009; 18(20):3987-96.
226. Zhang C, Browne A, Kim DY, Tanzi RE. Familial Alzheimer's Disease Mutations in Presenilin 1 Do Not Alter Levels of the Secreted Amyloid-beta Protein Precursor Generated by beta-Secretase Cleavage. *Curr Alzheimer Res*. 2009; In press.
227. Pihlajamäki M, O'Keefe K, Bertram L, Tanzi RE, Dickerson BC, Blacker D, Albert MS, Sperling RA. Evidence of Altered Posteromedial Cortical fMRI Activity in Subjects at Risk for Alzheimer Disease. *Alzheimer Dis Assoc Disord*. 2009; In press.
228. Fardo DW, Becker KD, Bertram L, Tanzi RE, Lange C. Recovering unused information in genome-wide association studies: the benefit of analyzing SNPs out of Hardy-Weinberg equilibrium. *Eur J Hum Genet*. 2009; In press.

Refereed Reviews

1. Watkins PC, Tanzi RE, Cheng SV, Gusella JF. Molecular genetics of human chromosome 21. *J. Med. Genet*. 1987; 76:121-126.

2. Tanzi RE, St. George-Hyslop PH, Gusella JF. Molecular biology of Alzheimer's disease. *Trends in Neuroscience* 1989; 12: 152-158.
3. Tanzi RE, McClatchey AI, Gusella JF. Molecular genetics of Alzheimer's disease and the amyloid beta protein precursor. *Annals of Medicine* 1989; 21: 91-94.
4. St. George-Hyslop PH, Myers RH, Haines JL, Farrer LA, Tanzi RE, Abe K, James MA, Polinsky R, Conneally PM, Gusella JF. Familial Alzheimer's disease: Progress and problems. *Neurobiol. Aging* 1989; 10: 417-427.
5. St. George-Hyslop PH, Haines JL, Tanzi RE, Polinsky RJ, Farrer L, Myers RH, Gusella JF. Molecular genetics of familial Alzheimer's disease. *Le Canadien des Sciences Neurologiques* 1989; 16: 1-3.
6. Tanzi RE and Haines JL. Problems in detecting heterogeneity by linkage studies. *Familial Alzheimer's Disease* eds. G Miner, RW Richter, JP Blass, L Winters-Miner, Marcel Dekker, Inc. N.Y. 1989; 183-193.
7. St. George-Hyslop PH, Polinsky RJ, Tanzi RE, Haines JL, Nee L, Growdon J, Pollen D, Drachman D, Myers RH, Feldman RG, Sullivan DO, Foncin J-F, Bruni SA, Salmon D, Ammaducci S, Sorbi S, Piacentini S, Frommelt P, Conneally PM, Gusella J. Familial and sporadic Alzheimer's disease: Molecular genetic approaches. *Familial Alzheimer's Disease* eds. G. Miner, RW Richter, JP Blass, L Winters Miner, Marcel Dekker, Inc. N.Y. 1989; 99-111.
8. St. George-Hyslop PH, Tanzi R, Haines JL, et al. Molecular genetic studies in autosomal dominant familial Alzheimer's disease. *Europ. Neurol.* 1989; 29: 25-27.
9. Tanzi RE and St. George-Hyslop PH. Familial Alzheimer's disease: Molecular Genetic Strategies. *Aging of the Brain* eds. T. Nagatsu and O. Hayaishi. Karger, Tokyo 1990; 161-175.
10. Tanzi RE and Gusella JF Detailed genetic linkage map of Human Chromosome 21: Patterns of recombination according to age and sex. *Molecular Genetics of Chromosome 21 and Down Syndrome. Prog. Clin. Biol. Res.* 1990; 360: 15-26.
11. Tanzi RE The Alzheimer's disease-associated amyloid beta protein precursor gene and familial Alzheimer's disease. *Molecular Genetics of Chromosome 21 and Down Syndrome. Prog. Clin. Biol. Res.* 1990; 360: 187-200.
12. Hyman BT, Beal MF, Tanzi RE. "Experimental Neurology" Invited chapter for The 1991 *Encyclopedia Britannica Medical and Health Volume*.
13. Duckett SH, Mafkind SH, Block T, Tanzi RE. Genetic Geriatric Neuropathology The Pathology of the Aging Human Nervous System eds. Serge H. Duckett, Lea and Febiger, Malvern, 1991; 336-364.
14. Tanzi RE, Romano DR, Huang TL, Wenniger JJ, Wasco W. Prevalence of APP gene

- mutations in familial Alzheimer's disease. *Bull. Clin. Neurosci.*, 1991; 56: 58-64.
15. Tanzi RE. Invited Editorial: Gene mutations in inherited amyloidopathies of the nervous system. *Am. J. Hum. Genet.* 1991; 49: 507-510.
 16. Tanzi RE. Genetic linkage studies of human neurodegenerative disorders. *Current Opinions in Neurobiology* 1991; 1: 455-461.
 17. Hyman BT and Tanzi RE. Amyloid, Dementia, and Alzheimer disease. *Current Opinions in Neurology* 1992; 5: 88-93.
 18. Tanzi RE and Hyman BT. Analysis of alternatively-transcribed messages in brain by in situ hybridization using biotinylated oligonucleotide probes. *In situ Hybridization in Neurobiology* ed. J. Barchas, Oxford Press, 1993; 131-142.
 19. Tanzi RE. Book Review: *The Molecular and Genetic Basis of Neurological Disease; Molecular Basis of Neurology*. *New Engl. J. Med.*, 1993; 329: 584-588.
 20. Wasco W and Tanzi RE. Molecular Genetics of Amyloid and Apolipoprotein E in Alzheimer's Disease. *Neurobiology of Alzheimer's Disease* eds. D. Dawbarn and S.J. Allen, BIOS Scientific Publishers, LTD, Oxford, 1995; 51-76.
 21. Hartstein J, Pace U, Hartstein ME, Tanzi RE, Bush AI. Editorial: Zinc and Macular degeneration. *Annals of Ophthalmology*, 1995; 27: 194-196.
 22. Tanzi RE. Clinical Implications of Basic Research: A promising animal model of Alzheimer's disease. *New Engl. J. Med.*, 1995; 332: 1512-1513.
 23. Hyman BT and Tanzi RE. Molecular Epidemiology of Alzheimer's Disease. *New Engl. J. Med.*, 1995; 333: 1283-1284.
 24. Wasco W. and Tanzi RE. Etiological Clues from Gene Defects Causing Early-Onset Familial Alzheimer's Disease. In: *Molecular Mechanisms of Dementia* eds. W. Wasco and R.E. Tanzi, Humana Press, New Jersey, 1996; 1-29.
 25. Atwood CS, Moir RD, Huang X, Tanzi RE, Bush AI. Cerebral Zinc Metabolism in Alzheimer's Disease. In: *Molecular Mechanisms of Dementia* eds. W. Wasco and R.E. Tanzi, Humana Press, New Jersey, 1996; 225-239
 26. Tanzi RE, Kovacs DM, Kim T-W, Moir RD, Guenette SY, Wasco W. The Presenilin Genes and Their Role in Early-Onset Familial Alzheimer's Disease. *Alzheimer's Disease Review*, 1996; 1: 91-98.
 27. Bush AI, Tanzi RE. The molecular biology of A β deposition in Alzheimer disease. *Principals of Neural Aging* (eds. Dani S.U., Hori A., Walter G.F), Elsevier Science B.V., Amsterdam, 1997; 103-109.
 28. Kim T-W, Tanzi RE. Presenilins and Alzheimer's Disease. *Current Opinion in*

- Neurobiology, 1997; 7: 683-688.
29. Finch CE. and Tanzi RE. Genetics of Aging. *Science* 1997; 278: 407-411.
 30. Tanzi, RE. The Molecular Genetics of Alzheimer's Disease in "Scientific American: Molecular Neurology", ed. Joseph B. Martin, Scientific American, New York, 1998; 55-75.
 31. Blacker D and Tanzi RE. The Genetics of Alzheimer's Disease: Current Status and Future Prospects. *Arch. Neurol.*, 1998; 55: 294-296.
 32. Tanzi, RE. and Finch CE. Presenilin interactions and Alzheimer's disease. *Science*, 1998; 279: 463-465.
 33. Tanzi, RE. The Role of Presenilins in Alzheimer's Disease. *Handbook of the Aging Brain* eds. Stephen Snyder and Eugenia Wang, Academic Press, 1998; 135-142.
 34. Kovacs, DM. and Tanzi RE. Monogenic determinants of FAD: Presenilin 1 Mutations. *Cell. Mol. Life Sci.*, 1998; 54: 902-909.
 35. Tanzi RE. Of Calcium, Caspases, and Cognitive Decline, *Nature Medicine*, 1998; 4: 1153-1155.
 36. O'Malley C.O., Saunders A, Bush A, Tanzi R. Potential therapeutic targets for Alzheimer's disease. *Emerging Therapeutic Targets* 1998; 2: 1-23.
 37. Kim T.-W. and Tanzi R.E. Neuronal intranuclear inclusions in polyglutamine diseases: Nuclear weapons or nuclear fallout. *Neuron* 1998; 21: 1-20.
 38. Price DL., Tanzi RE., Borchelt DR., Sisodia SS. Alzheimer's disease: Genetic studies and transgenic models. *Annu. Rev. Genet.* 1998; 32: 461-493.
 39. Bush AI, Tanzi RE. Alzheimer disease-related abnormalities of amyloid beta protein isoforms in the platelet. *Arch. Neurol.*, 1998; 55: 1179-1180.
 40. Guenette S, Tanzi RE. The FE65 proteins: A role in the pathology of Alzheimer's disease? *Current Research in Alzheimer's Disease*. 1999.
 41. Atwood C.S., Huang X., Moir R.D., Tanzi R.E., Bush A.I. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. *Metal Ions in Biological Systems (Volume 36)* eds. A. Sigel and H. Sigel, Marcel Dekker, Inc. New York, Basel 1999; 309-345.
 42. Huang X, Cuajungco M, Atwood CS, Moir RD, Tanzi RE, Bush AI. Alzheimer's disease, β -amyloid protein and zinc. *Journal of Nutrition* 1999.
 43. Moir RD, Atwood CS, Huang X, Tanzi RE, Bush AI. Mounting evidence for the involvement of zinc and copper in Alzheimer's disease. *Eur. J. Clin. Invest.* 1999; 29 :569-570.

44. Guenette S, Tanzi R.E. Progress towards valid transgenic mouse models for Alzheimer's disease. *Neurobio.of Aging*, 1999; 20: 201-211.
45. Cuajungco M.P., Lees G.J., Kydd R.R., Tanzi R.E., Bush A.I. Zinc and Alzheimer's Disease: An Update. *Nutritional Neuroscience*, 1999; 2: 191-208.
46. Tanzi RE. Caspases land on APP: One small step for apoptosis, one giant leap for amyloidosis? *Nature Neuroscience* 1999; 2: 585-586
47. Tanzi RE. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. *J. Clin. Invest.* 1999; 104: 1175-1179.
48. Tanzi RE. Alzheimer's disease risk and the interleukin-1 genes. *Ann. Neurol.* 2000; 47: 283-285
49. Blacker, D., and Tanzi, R. E. "Genetic testing in the early diagnosis of Alzheimer's disease." In *Early Diagnosis Of Alzheimer's Disease*", Humana Press, New Jersey, 2000; 105-125.
50. Tanzi RE Alzheimer's disease and related dementias: the road to intervention. *Exp. Gerontol.* 2000 35: 433-437.
51. McKeon-O'Malley C, Tanzi RE. Etiology, Genetics, and Pathogenesis of Alzheimer's Disease. In *Functional Neurobiology of Aging* (eds. Hof, PR, Mobbs, CV) Academic Press, San Diego 2001; 333-341.
52. Bertram L, Tanzi RE. Dancing in the dark? The Status of Late-Onset Alzheimer's Disease Genetics." *J Mol Neurosci* 2001 17: 127-136
53. Bertram L, Tanzi RE. Of replications and refutations: The status of Alzheimer's disease genetics research." *Curr Neurol Neurosci Rep* 2001 1: 442-452.
54. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics." *Neuron* 2001 32: 181-184.
55. Tanzi RE. Strategies for the post-genomic era. *Red Herring Magazine*, June, 2002.
56. Bush AI, Tanzi RE. The galvanization of beta-amyloid in Alzheimer's disease. *Proc Natl Acad Sci U S A.* 2002 99:7317-7319.
57. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. *Nature Neurosci.* 2003 6:345-351.
58. Bush AI, Masters CL, Tanzi RE. Copper, β -amyloid and Alzheimer's disease: tapping a sensitive connection. *Proc. Natl. Acad. Sci. (USA)* 2003 100: 11193-1119.
59. Saunders AJ, Tanzi RE Welcome to the complex disease world. Alpha2-macroglobulin and Alzheimer's disease. *Exp Neurol.* 2003 184: 50-53.

60. Bertram L, Tanzi RE The Current Status of Alzheimer's Disease Genetics: What Do We Tell The Patients? *Pharmacol Res.* 2004 50: 385-396.
61. Bertram L, Tanzi RE Alzheimer's Disease: One Disorder. Too Many Genes? *Hum. Mol. Genet.*, 2004, 13: R135-141.
62. Tanzi, RE, Moir, RD, Wagner, S. Clearance of Alzheimer's A β peptide: The many roads to perdition. *Neuron*, 2004, 43: 605–608.
63. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. *J. Clin. Invest.*, 2005; 115:1449-1457.
64. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. *Cell*, 2005; 120: 545-555.
65. Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. *Nat Neurosci.*, 2005; 8: 977-979.
66. Tanzi RE Tangles and neurodegenerative disease--a surprising twist. *N Engl J Med.* 2005; 17:1853-1855.
67. Huang X, Moir RD, Tanzi RE, Bush¹ AI, Rogers JT Metal and Alzheimer's disease. *Annals of the New York Academy of Science, Ann N Y Acad Sci.* 2004; 1012:153-163.
68. Bertram L, Tanzi RE "Genetics of Alzheimer's Disease"; In: *Neurodegenerative Diseases - Neurobiology, Pathogenesis, and Therapeutics*; Editors: Beal MF, Lang AE, Ludolph A; Cambridge University Press; pp. 441-451.
69. Xie, Z. and Tanzi, RE. Alzheimer's Disease Dementia and Post-operative Cognitive Dysfunction. *Experimental Gerontology.* 2006; 41:346–359.
70. Bush AI and Tanzi RE. Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis. *Neurotherapeutics.* 2008; 5:421-432.
71. Tanzi RE. Novel Therapeutics for Alzheimer's Disease. *Neurotherapeutics.* 2008; 5:377-380.
72. Tanzi RE and Bertram L. Alzheimer's Disease: The Latest Suspect. *Nature* 2008; 454:706-708.
73. Bertram L and Tanzi RE. Thirty Years of Alzheimer's Disease Genetics: Systematic Meta-analyses Herald a New Era. *Nature Reviews Neurosci* 2008; 9:768-78.
74. Hooli BV and Tanzi RE. A current view of Alzheimer's disease. *F1000 Biology Reports* 2009, 1:54-57.
75. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer's disease. *Hum Mol Genet* 2009 Oct 15;18(R2):R137-145.

Proceedings of Meetings (Articles and Book)

1. Gusella JF, Watkins PC, Tanzi RE, Anderson MA, Ottina K. The use of restriction fragment length polymorphisms to map the Huntington's disease gene. *Banbury Reports* 1983; 14: 261-265.
2. Gusella JF, Tanzi RE, Watkins PC, Gibbons KT, Hobbs WJ, Faryniarz AG, Healy ST, Anderson MA. Genetic linkage map for human chromosome 21. *Ann. NY. Acad.Sci.* 1985; 450: 25-31.
3. Gusella JF, Gilliam TC, Tanzi RE, MacDonald ME, Cheng SV, Wallace MR, Haines JL, Conneally PM, Wexler NS. Molecular genetics of Huntington's disease. *Cold Spring Harbor Symposium on Quantitative Biology* 1986; Vol. LI: 359-364.
4. St. George-Hyslop PH, Tanzi RE, Hobbs WJ, Gibbons KT, Gusella JF, Nee L, Polinsky RJ, Haines JL, Conneally PM. DNA markers in familial Alzheimer's disease in: *New Concepts in Alzheimer's Disease*. Eds.: M. Briley, A. Kato, M. Weber. Macmillan, London 1986; 257-265.
5. Seizinger BR, Tanzi RE, Gilliam TC, Bader JL, Parry DM, Spence AM, Marazita ML, Gibbons KT, Hobbs WJ, Gusella JF. Genetic linkage analysis of neurofibromatosis with DNA markers. *Ann. N.Y. Acad. Sci.* 1986; 486: 304-311.
6. Tanzi RE, Gusella JF. Molecular biology of the Alzheimer's amyloid beta peptide precursor gene. *FESN: Discussions in Neuroscience*. Eds.: Paul Brown, Liana Bolis and Carlton Gajdusek, 1988; V, No 3: 47-51.
7. St. George-Hyslop PH, Tanzi RE, Watkins PC, Haines JL, Nee L, Polinsky RJ, Gusella JF. Molecular genetic approaches to familial Alzheimer's disease. *FESN: Discussions in Neuroscience*. Eds. Paul Brown, L. Bolis and C. Gajdusek, 1988; V, No 3: 89-91.
8. MacDonald ME, Tanzi RE, Gusella JF. Molecular genetics of Huntington's disease. *FESN: Discussions in Neuroscience*. Eds. Paul Brown, L. Bolis, C. Gajdusek, 1988; V, No 3: 107-109.
9. Gusella JF, St. George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Stewart GD, Neve RL, Bruns GA, Myers RH, Feldman RG, Pollen D, Drachman D, Bruni A, Foncin J-F, Frommelt P, Amaducci L, Conneally, PM. Genetic linkage analysis of familial Alzheimer's disease. *Banbury Report 27: Molecular Neuropathology of Aging*, Cold Spring Harbor Laboratory 1988; 425-441.
10. Tanzi RE, McClatchey AI, Gusella JF. Molecular genetics of the Alzheimer's Amyloid Peptide Precursor Gene. *Current Communications in Molecular Biology: The Molecular Biology of Alzheimer's Disease*, eds. Caleb E. Finch and Peter Davies, Cold Spring Harbor Laboratory 1988; 95-101.
11. St. George Hyslop PH, Haines J, Farrer L, Tanzi RE et al. Molecular genetics of autosomal

- dominant familial Alzheimer's disease. *Current Communications in Molecular Biology: The Molecular Biology of Alzheimer's Disease*, eds. Caleb E. Finch and Peter Davies, Cold Spring Harbor 1988; 159-169
12. St. George-Hyslop PH, Farrer L, Haines J et al. Molecular genetic strategies in familial Alzheimer's disease: Theoretical and practical considerations. *Genetics and Alzheimer's Disease* eds. PM Sinet, Y Lamour, Y Christen, Fondation IPSEN, Springer-Verlag Berlin 1988; 109-116.
 13. Tanzi RE, St. George-Hyslop PH, James M, Haines JL, Gusella JF. Genetics studies of the Alzheimer's disease-associated amyloid beta-protein precursor gene and familial Alzheimer's disease. in: *Biological Markers in Alzheimer's Disease* Eds.: F. Boller, R. Katzman, a Rascol, J-L Signoret, Y. Christen, Fondation IPSEN, Springer-Verlag, Berlin 1989: 130-138.
 14. Tanzi RE A serine protease inhibitor domain encoded within the Alzheimer disease-associated amyloid- β -protein precursor gene. in: *Serine Proteases and Their Inhibitors in the Nervous System* editor: Barry Festoff. Plenum Press, New York 1990 NATO ASI Series A: Life Sciences Vol. 191: 313-318.
 15. Tanzi RE and Hyman BT. Studies of Amyloid beta protein precursor expression in Alzheimer's disease. *Annals N.Y. Acad. Sci.* 1991; 640: 149-155.
 16. Tanzi RE. What can we learn from the genetics of Alzheimer's disease? Dahlem Workshop Reports: Neurodegenerative disorders: Mechanisms and Prospects for Therapy, Life Sciences Research Report., 1991; 51: 61-75.
 17. St George-Hyslop P, Crapper McLachlan DR, Haines JL, Lukiw W, Mortilla M, Sorbi S, Tanzi R, Tupler R, Vaula G. Molecular genetic evidence for etiologic heterogeneity of Alzheimer disease. in: *Heterogeneity of Alzheimer's Disease* eds. F. Boller, F. Forette, Z Khachaturian, M Poncet, Y. Christen, Fondation IPSEN, Springer-Verlag Berlin 1992; 88-95.
 18. Wasco W and Tanzi RE. Search for genes responsible for Familial Alzheimer's disease. Zurich VII, *Annals N.Y. Acad. Sci.* 1993; 695: 203-209.
 19. Wasco W, Hyman BT, Tanzi RE. Amyloid precursor-like protein: A member of the highly conserved APP gene family. *Advances in the Biosciences Volume 87: Alzheimer's disease and related disorders* eds. M. Nicolini, P.F. Zatta, B. Corain, Pergamon Press Oxford, 1993; 229-233.
 20. Bush AI, Pettingell W, Wasco W, Tanzi RE. The roles of zinc and copper in the function and metabolism of the amyloid protein precursor super family. *Amyloid Protein Precursor in Development, Aging, and Alzheimer's Disease* eds. C.L. Masters, K. Beyreuther, M. Trillet, Y. Christin, Fondation IPSEN, Springer-Verlag Berlin 1994; 169-180.
 21. Tanzi RE, Romano D, Gaston S, Crowley A, Bush A, Peppercom J, Paradis M, Pettingell W, Gurubhagavatula S, Kovacs D, Haines J, St George-Hyslop P, Wasco W. The diverse

- molecular nature of inherited Alzheimer's disease. Amyloid Protein Precursor in Development, Aging, and Alzheimer's Disease eds. C.L. Masters, K. Beyreuther, M. Trillet, Y. Christin, Fondation IPSEN, Springer-Verlag Berlin 1994, 181-189.
22. Wasco W, Gurubhagavatula S, Tanzi RE. Molecular characterization of members of the APP-like gene family. *Research Advances in Alzheimer's Disease and Related Disorders*, eds. K. Iqbal, J. Mortimer, B. Winblad, H. Wisniewski, John Wiley and Sons LTD, West Sussex, 1995; 657-667.
 23. Bush AI and Tanzi RE. The role of zinc in the cerebral deposition of A β amyloid in Alzheimer's disease. *Research Advances in Alzheimer's Disease and Related Disorders*, eds. K. Iqbal, J. Mortimer, B. Winblad, H. Wisniewski, John Wiley and Sons, West Sussex, 1995; 607-618.
 24. Tanzi RE. Analysis of the genes responsible for Alzheimer's disease. *20 Years of Brain Research in Kuopio*. eds. T. Salonen, J. Sivenius, J. Sirvio, P. Riekkinen, A. Salminen., U. of Kuopio 1996, 16-23.
 25. Tanzi RE, Kim T-W, Kovacs DM, Guenette SY, Moir RD, Hyman BT Wasco W. The Genes Responsible for Familial Alzheimer's Disease: Toward a Common Etiological Pathway. *Alzheimer's Disease: Biology, Diagnosis, and Therapeutics* (eds. K. Iqbal, B. Winblad, T. Nishimura, M. Takeda, H.M. Wisniewski, John Wiley and Sons LTD, West Sussex, 1997; 63-69.
 26. Kim T-W, Hallmark OG, Pettingell WH, Wasco W, Tanzi RE. Proteolytic Processing and Ubiquitin-Proteasomal Degradation of Wild-Type and Mutant Forms of Presenilin 2. *Alzheimer's Disease: Biology, Diagnosis, and Therapeutics* (eds. K. Iqbal, B. Winblad, T. Nishimura, M. Takeda, H.M. Wisniewski), John Wiley and Sons LTD, West Sussex, 1997; 576-582.
 27. Atwood CS, Huang X, Moir RD, Tanzi RE, Bush AI. Neurochemical Environments that Precipitate Alzheimer's Disease: *Biology, Diagnosis, and Therapeutics* (eds. K. Iqbal, B. Winblad, T. Nishimura, M. Takeda, H.M. Wisniewski), John Wiley and Sons LTD, West Sussex, 1997; 327-336.
 28. Huang X, Atwood CS, Goldstein, LE, Hartshorn MA, Sanders AJ, Moir RD, Tanzi RE, Bush AI. Metal-catalyzed Redox activity of A β The major source of amyloid-associated oxidative stress in Alzheimer's disease. *Alzheimer's Disease: Biology, Diagnosis, and Therapeutics* (eds. K. Iqbal, B. Winblad, T. Nishimura, M. Takeda, H.M. Wisniewski), John Wiley and Sons LTD, West Sussex, 1997.
 29. Tanzi RE, Kim TW, Kovacs DM, Wasco W, Moir R, Pettingell W, Henderson J, Mancini R. Alternative endoproteolysis of the presenilins and familial Alzheimer's disease. *Presenilins and Alzheimer's Disease*. eds. S.G. Younkin, R.E. Tanzi, Y. Christin, Fondation IPSEN, Springer-Verlag Berlin 1998; 19-26.
 30. Wasco W. Tanzi RE, Moir RD, Crowley AC, Merriam DE, Romano DM, Jondro PD, Kellerman BA. Presenilin 2-APP Interactions. *Presenilins and Alzheimer's Disease*. eds.

- S.G. Younkin, R.E. Tanzi, Y. Christin, Fondation IPSEN, Springer-Verlag Berlin 1998; 59-70.
31. Kovacs DM, Na SJ, Tanzi RE. Presenilin mutations in Alzheimer's disease. *Clinical Neuroscience*, 1998; 51: 24-25.
 32. Kovacs DM, Mancini R, Na SJ, Kim T-W, Tanzi RE. Caspase cleavage of presenilin 1 is increased in apoptotic cells as a result of familial Alzheimer's disease mutations. in *Alzheimer's Disease and Related Disorders* (eds. Iqbal K, Swaab DF, Winblad B, Wisniewski HM), 1999; 607-612.
 33. Tesco G, Kim T-W, Tanzi RE. Caspase cleavage abolishes molecular interaction between presenilin-1 and β -catenin. in *Alzheimer's Disease and Related Disorders* (eds. Iqbal K, Swaab DF, Winblad B, Wisniewski HM), 1999; 347-351.
 34. Huang X., Atwood CS., Goldstein LE., Hartshim MA., Saunders AJ., Moir RD., Tanzi RE., Bush AI. Metal-catalyzed redox activity of A β -the major source of amyloid-associated oxidative stress in Alzheimer's disease. in *Alzheimer's Disease and Related Disorders* (eds. Iqbal K, Swaab DF, Winblad B, Wisniewski HM), 1999; 383-390.
 35. Guenette SY., Chen J., Ferland A., Tanzi RE. hFE65L over-expression enhances β -amyloid precursor protein maturation and processing. in *Alzheimer's Disease and Related Disorders* (eds. Iqbal K, Swaab DF, Winblad B, Wisniewski HM), 1999; 591-598.
 36. Kovacs, DM. Alpha2-macroglobulin in late-onset Alzheimer's disease. *Exp. Geront.* 2000, 35:473-479.
 37. Tesco G, Tanzi RE GSK3 β forms a tetrameric complex with endogenous PS1-CTF/NTF and alpha-catenin. In *Molecular Basis of Dementia* (eds: Growdon J et al) *Annals of the New York Academy of Science*, Volume 920, 2000: 227-232.
 38. MacKenzie-Ingano LA, Lentini KM, Kovacs I, Tanzi RE, Kovacs DM. Cytoplasmic presenilin aggregates in proteasome inhibitor-treated cells. In *Molecular Basis of Dementia* (eds: Growdon J et al) *Annals of the New York Academy of Science*, Volume 920, 2000: 259-260.
 39. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. In *Molecular Basis of Dementia* (eds: Growdon J et al) *Annals of the New York Academy of Science*, Volume 920, 2000: 292-304.
 40. Puglielli, L, MacKenzie Ingano, LA, Tanzi, RE, Kovacs, DM. The amyloid precursor protein V717I mutation increases susceptibility to cell death in a cholesterol-dependent manner. In *Alzheimer's disease: Advances in Etiology, Pathogenesis and Therapeutics*. (eds: Iqbal, K. et al.) John Wiley & Sons Ltd., 2001: 469-477.
 41. Bertram L, Blacker D, Crystal A, Jones J, Keeney D, MacKenzie-Ingano ., Mullin K, Basu S, Yhu S, McInnis M, Go RCP, Saunders AJ, Tanzi RE. Candidate Genes Showing No Evidence of Association with AD: Results of the NIMH-AD Genetics Initiative." In:

- Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (eds. Iqbal K. et al) John Wiley & Sons, 2001: 45-52.
42. Albert MS, Killiany RJ, Johnson K, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. In: Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (eds. Iqbal K. et al) John Wiley & Sons, 2001: 97-99.
 43. Atwood CS., Huang X., Moir RD., Smith MA., Tanzi RE., Roher AE., Bush Ai., Perry G. Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational modification of amyloid deposits. In: Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (eds. Iqbal K. et al) John Wiley & Sons, 2001: 341-363.
 44. Cheng I, Yoo A, Tanzi RE., Kim T-W. Familial Alzheimer's disease-linked mutant presenilins attenuate capacitative calcium entry. In: Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (eds. Iqbal K. et al) John Wiley & Sons, 2001: 515-520.
 45. Bertram L, Blacker D, Mullin K, Parkinson M, Sampson A, Moscarillo T, Saunders AJ, Tanzi RE. A High-Resolution Alzheimer's Disease Genome Screen: Evidence For Genetic Linkage On Twelve Chromosomes. In: Alzheimer's Disease (eds. Iqbal K. et al) John Wiley & Sons, 2003.
 46. Moir RD, Tanzi RE. Protein aggregation and human disorders. In "Encyclopedia of the Human Genome." Nature Publishing Group, 2003.
 47. Bertram L, Tanzi RE "Genetics of Neurodegenerative Diseases"; In: Basic Neurochemistry, 7th Edition; Editors: Siegel GJ, Albers RW, Brady, S, Price D; Elsevier Publishing; pp. 653-666. Bertram L and Tanzi RE, Genetics of Alzheimer's Disease, 2005.

Books, Monographs, and Text Books (Published Only):

1. Molecular Mechanisms of Dementia editors. W. Wasco and R.E. Tanzi, Humana Press, New Jersey, 1996.
2. Presenilins and Alzheimer's Disease. editors. S.G. Younkin, R.E. Tanzi, Y. Christin, Fondation IPSEN, Springer-Verlag Berlin 1998.
3. The Aging Mind (as part of the National Research Council Committee on Future Directions for Cognitive Research on Aging) eds. Paul C. Stern, Laura Carstensen, National Academy Press, Washington D.C. 2000.
4. Decoding Darkness: The Search for the Genetic Causes of Alzheimer's Disease. RE Tanzi and A Parson, Perseus Publishing, N.Y. 2000.
5. Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology; Editors: Sisodia S, Tanzi RE; Springer Press, 2006.

Patents:

1. Tanzi, RE and Gilliam T.C. Isolation and uses of the Wilson's Disease Gene. Issued.
2. Tanzi RE, Kovacs DM. Methods for modulating transcription from the Amyloid β Protein Precursor (APP) Promotor. Issued.
3. Wasco, WW, Tanzi RE, Solomon F., Bupp K, Magendantz M. Amyloid Precursor-Like Protein and uses thereof. Issued.
4. Tanzi RE, Bush AI, Moir RD, A Diagnostic Assay for Alzheimer's Disease: Assessment of A β Abnormalities. Issued.
5. Strickland D, Kounnas M, Hyman BT, Moir RD, Tanzi RE. Modulators of expression and function of LRP in Alzheimer's disease. Issued.
6. Tanzi RE, Bush AI, An In Vitro System for Determining Formation of A β Amyloid. Issued.
7. Bush AI, Huang X, Atwood CS, Tanzi RE, inventors; Massachusetts General Hospital assignee. Method for the Identification of Agents for Use in the Treatment of Alzheimer's Disease. Issued.
8. Tanzi RE, Schellenberg GD, Wasco W, Bird TD, Galas DJ. Chromosome 1 gene and gene products related to Alzheimer's disease. Issued.
9. Tanzi RE and Wasco W. Genetic alterations related to familial Alzheimer's disease. Issued.
10. Bush AI, Xilinas M, Tanzi RE, Use of Clioquinol for the Therapy of Alzheimer's Disease. Pending
11. Bush AI, Huang X, Atwood CS, Tanzi RE, Agents for Use in the Treatment of Alzheimer's Disease. Issued
12. Tanzi RE and Kim T-W. A purified 20 kDa presenilin 2 C-terminal fragment and methods for screening for compounds that inhibit proteolysis of presenilin 2. Pending.
13. Tanzi RE, Diagnosis of Alzheimer's disease based on α 2-macroglobulin. Issued
14. Tanzi RE, Kovacs DM, Saunders A. Alpha2-macroglobulin Therapies for Alzheimer's Disease. Issued.
15. Kim T-W, Tanzi RE, Modulation of CCE as a method for treating Alzheimer's disease. Pending.
16. Becker D et al. Genes and Polymorphisms on Chromosome 10 Associated with Alzheimer's Disease and other Neurodegenerative Diseases Pending

17. Tanzi RE et al. Genetics markers for Alzheimer's disease and methods using the same. Pending.
18. Becker D et al. Single Nucleotide Polymorphisms and Mutations on Alpha-2-Macroglobulin, Pending.
19. Tanzi RE. et al. Methods of Use, Compositions and Kits for Single Nucleotide Polymorphisms of UBQLN1, Pending.